
<html lang="en"     class="pb-page"  data-request-id="1baeaf55-7118-45a8-a6a7-4dabb1d70173"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-11;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.8b00499;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers" /></meta><meta name="dc.Creator" content="Michael  Grasso" /></meta><meta name="dc.Creator" content="Michelle A.  Estrada" /></meta><meta name="dc.Creator" content="Kiara N.  Berrios" /></meta><meta name="dc.Creator" content="Jeffrey D.  Winkler" /></meta><meta name="dc.Creator" content="Ronen  Marmorstein" /></meta><meta name="dc.Description" content="BRAFV600E is the most common activating mutation in melanoma and patients treated with BRAFV600E inhibitors all develop resistance within one year. A significant resistance pathway is paradoxical a..." /></meta><meta name="Description" content="BRAFV600E is the most common activating mutation in melanoma and patients treated with BRAFV600E inhibitors all develop resistance within one year. A significant resistance pathway is paradoxical a..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 4, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00499" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00499" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00499" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00499" /></link>
        
    
    

<title>N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00499" /></meta><meta property="og:title" content="N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0010.jpeg" /></meta><meta property="og:description" content="BRAFV600E is the most common activating mutation in melanoma and patients treated with BRAFV600E inhibitors all develop resistance within one year. A significant resistance pathway is paradoxical activation (transactivation) involving BRAF dimers, whereby an inhibitor bound protein subunit allosterically activates the other subunit. We recently reported on dimeric BRAFV600E -selective vemurafenib inhibitors that stabilize an inactive αC-out/αC-out homodimeric conformation with improved inhibitor potency and selectivity in vitro. We set out to extend this strategy to target RAF homo- and heterodimers with the pan-RAF inhibitor TAK632 in dimeric configuration. Surprisingly, we find that monomeric TAK632 induces an active αC-in/αC-in BRAF dimer conformation, while dimeric TAK inhibitors cannot promote BRAF dimers and have significantly compromised potency in vitro. These studies uncover the intimate connection between BRAF dimerization and TAK632 mode of inhibition and highlight the importance of understanding the impact of BRAF inhibitors on kinase dimerization." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00499"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00499">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00499&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00499&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00499&amp;href=/doi/10.1021/acs.jmedchem.8b00499" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 5034-5046</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00477" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00484" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title"><i>N</i>-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Michael Grasso</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Grasso</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics and the Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, United States</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Grasso">Michael Grasso</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle A. Estrada</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle A. Estrada</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle+A.++Estrada">Michelle A. Estrada</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kiara N. Berrios</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kiara N. Berrios</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics and the Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kiara+N.++Berrios">Kiara N. Berrios</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey D. Winkler</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey D. Winkler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States</div></div><span class="conrtib-corresp"><strong>*</strong>For J.D.W.: E-mail <a href="/cdn-cgi/l/email-protection#2057494e4b4c4552605341530e5550454e4e0e454455"><span class="__cf_email__" data-cfemail="bacdd3d4d1d6dfc8fac9dbc994cfcadfd4d494dfdecf">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+D.++Winkler">Jeffrey D. Winkler</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8264-5491" title="Orcid link">http://orcid.org/0000-0001-8264-5491</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ronen Marmorstein</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ronen Marmorstein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics and the Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, United States</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States</div></div><span class="conrtib-corresp"><strong>*</strong>For R.M.: phone, 215-898-7740; fax, 215-746-5511; E-mail, <a href="/cdn-cgi/l/email-protection#d0bdb1a2bdbfa290a5a0b5bebefeb5b4a5"><span class="__cf_email__" data-cfemail="6a070b180705182a1f1a0f0404440f0e1f">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ronen++Marmorstein">Ronen Marmorstein</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4373-4752" title="Orcid link">http://orcid.org/0000-0003-4373-4752</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00499&amp;href=/doi/10.1021%2Facs.jmedchem.8b00499" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 5034–5046</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 4, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 March 2018</li><li><span class="item_label"><b>Published</b> online</span>4 May 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 June 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00499" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00499</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5034%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMichael%2BGrasso%252C%2BMichelle%2BA.%2BEstrada%252C%2BKiara%2BN.%2BBerrios%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D11%26contentID%3Dacs.jmedchem.8b00499%26title%3DN-%25287-Cyano-6-%25284-fluoro-3-%25282-%25283-%2528trifluoromethyl%2529phenyl%2529acetamido%2529phenoxy%2529benzo%255Bd%255Dthiazol-2-yl%2529cyclopropanecarboxamide%2B%2528TAK632%2529%2BPromotes%2BInhibition%2Bof%2BBRAF%2Bthrough%2Bthe%2BInduction%2Bof%2BInhibited%2BDimers%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5046%26publicationDate%3DJune%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00499"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1151</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00499" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Grasso&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;A. Estrada&quot;},{&quot;first_name&quot;:&quot;Kiara&quot;,&quot;last_name&quot;:&quot;N. Berrios&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;D. Winkler&quot;},{&quot;first_name&quot;:&quot;Ronen&quot;,&quot;last_name&quot;:&quot;Marmorstein&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;5034-5046&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00499&quot;},&quot;abstract&quot;:&quot;BRAFV600E is the most common activating mutation in melanoma and patients treated with BRAFV600E inhibitors all develop resistance within one year. A significant resistance pathway is paradoxical activation (transactivation) involving BRAF dimers, whereby an inhibitor bound protein subunit allosterically activates the other subunit. We recently reported on dimeric BRAFV600E -selective vemurafenib inhibitors that stabilize an inactive αC-out/αC-out homodimeric conformation with improved inhibitor potency and selectivity in vitro. We set out to extend this strategy to target RAF homo- and heterodimers with the pan-RAF inhibitor TAK632 in dimeric configuration. Surprisingly, we find that monomeric TAK632 induces an active αC-in/αC-in BRAF dimer conformation, while dimeric TAK inhibitors cannot promote BRAF dimers and have significantly compromised potency in vitro. These studies uncover the intimate connection between BRAF dimerization and TAK632 mode of inhibition and highlight the importance of understanding t&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00499&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00499" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00499&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00499" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00499&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00499" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00499&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00499&amp;href=/doi/10.1021/acs.jmedchem.8b00499" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00499" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00499" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00499%26sid%3Dliteratum%253Aachs%26pmid%3D29727562%26genre%3Darticle%26aulast%3DGrasso%26date%3D2018%26atitle%3DN-%25287-Cyano-6-%25284-fluoro-3-%25282-%25283-%2528trifluoromethyl%2529phenyl%2529acetamido%2529phenoxy%2529benzo%255Bd%255Dthiazol-2-yl%2529cyclopropanecarboxamide%2B%2528TAK632%2529%2BPromotes%2BInhibition%2Bof%2BBRAF%2Bthrough%2Bthe%2BInduction%2Bof%2BInhibited%2BDimers%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D11%26spage%3D5034%26epage%3D5046%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292425" title="Oligomers">Oligomers</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291026" title="Conformation">Conformation</a>,</li><li><a href="/action/doSearch?ConceptID=290899" title="Dimerization">Dimerization</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/jmcmar.2018.61.issue-11/20180614/jmcmar.2018.61.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">BRAF<sup>V600E</sup> is the most common activating mutation in melanoma and patients treated with BRAF<sup>V600E</sup> inhibitors all develop resistance within one year. A significant resistance pathway is paradoxical activation (transactivation) involving BRAF dimers, whereby an inhibitor bound protein subunit allosterically activates the other subunit. We recently reported on dimeric BRAF<sup>V600E</sup> -selective vemurafenib inhibitors that stabilize an inactive αC-out/αC-out homodimeric conformation with improved inhibitor potency and selectivity in vitro. We set out to extend this strategy to target RAF homo- and heterodimers with the pan-RAF inhibitor TAK632 in dimeric configuration. Surprisingly, we find that monomeric TAK632 induces an active αC-in/αC-in BRAF dimer conformation, while dimeric TAK inhibitors cannot promote BRAF dimers and have significantly compromised potency in vitro. These studies uncover the intimate connection between BRAF dimerization and TAK632 mode of inhibition and highlight the importance of understanding the impact of BRAF inhibitors on kinase dimerization.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68076" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68076" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The MAPK pathway is a key regulator of cell proliferation through its control of protein translation and transcription factor regulation via signal transduction. The BRAF kinase within this pathway is a significant oncoprotein, resulting in about 50% of melanomas and a significant number of other cancers including colorectal, ovarian, and lung cancers, among others.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> A large percentage of BRAF-mutated cancers result from a valine to glutamic acid point mutation at residue 600, stabilizing an active kinase conformation and triggering unregulated progression of the MAPK signaling cascade.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Because of the prominent driver role of mutant BRAF in melanoma and other cancers, significant effort has been invested toward BRAF inhibitor development and in particular to inhibiting oncogenic BRAF<sup>V600E</sup>. While mutant-specific inhibitors such as vemurafenib and dabrafenib have been approved by the FDA to treat patients with metastatic BRAF<sup>V600E</sup> melanoma,<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> almost all patients develop drug resistance within 6 months of treatment.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> These drug resistance pathways usually involve MAPK pathway reactivation, such as mutation or upregulation of upstream RAS or receptor tyrosine kinases (RTKs) or downstream MEK.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Moreover, while many inhibitors targeting RAF kinases have been developed, most of these compounds have the ability to paradoxically activate (transactivate) BRAF kinases, which typically signal as dimers, at subsaturating concentrations.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Indeed, when activated RAS is present, low concentrations of inhibitor can bind one protomer of a BRAF dimer, allosterically activating the other protomer and hyperactivating the MAPK pathway. This plays a prominent role in inhibitor resistance, as upregulation of upstream kinases such as RAS or RTKs due to resistance pathways can trigger dimerization and, in turn, trigger paradoxical activation.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Another form of resistance in BRAF<sup>V600E</sup> tumors is the expression of a splice variant of BRAF<sup>V600E</sup> that does not include the RAS binding domain (RBD), leading to enhanced dimerization that is also vulnerable to paradoxical activation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> A recent study reported on the development of inhibitors that can escape paradoxical activation, and these “paradox breaker” inhibitors modify the propyl sulfonamide tail of vemurafenib, which is hypothesized to shift the αC-helix into a dimer-destabilizing orientation.<a onclick="showRef(event, 'ref8 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref8 ref14 ref15 ref16">(8,14−16)</a> However, crystal structures of BRAF in complex with paradox breaker inhibitors still form BRAF dimers with αC-helix orientations similar to BRAF kinase dimers with vemurafenib.<a onclick="showRef(event, 'ref14 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref14 ref18 ref19">(14,18,19)</a> Moreover, these structures also have one BRAF protomer bound to inhibitor while the other is not, and the unbound subunit of the kinase dimer has the αC-helix shifted toward the inward (active) conformation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This raises the possibility of drug resistance developing in patients treated with paradox breaker inhibitors, one of which, PLX8394, is currently in clinical trials (NCT02428712).<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a></div><div class="NLM_p">The studies described above highlight the importance of understanding different BRAF inhibitor binding modes and their effects on BRAF dimerization and activation. A prior study characterized several RAF kinase inhibitors that can induce dimerization in vitro and in cells and correlated this to the stabilization of a closed conformation of N and C lobes of the kinase.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> A more recent study comparing eight diverse RAF inhibitors led to their classification according to their ability to promote an active or inactive αC-helix conformation, αC-in versus αC-out, respectively. The authors determined that the more BRAF mutant-specific αC-out inhibitors (such as vemurafenib) are correlated with inhibitor resistance due to negative allostery, in which one subunit of the RAF dimer binds the inhibitor in the αC-out conformation, rendering the other subunit in an inhibitor-free αC-in conformation that promotes paradoxical activation.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In contrast, the less BRAF mutant-selective pan-RAF αC-in inhibitors can occupy both active sites of a BRAF dimer and are therefore less correlated with drug resistance during treatment.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p last">We previously reported on the development of dimeric vemurafenib (type I) inhibitors as a novel approach to potently inhibit active BRAF<sup>V600E</sup> dimers.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> We found that these inhibitors promote an inactive BRAF<sup>V600E</sup>/BRAF<sup>V600E</sup> homodimeric conformation with both protomers in αC-out conformations and with improved vemurafenib potency and selectivity for BRAF<sup>V600E</sup> in vitro.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> To evaluate the BRAF dimerization and inhibition properties of dimeric inhibitors that contain a compound that promotes an αC-in conformation, we employed the type II αC-in inhibitor TAK632.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> We hypothesized that a dimeric TAK inhibitor would further stabilize an inactive dimeric BRAF conformation. Surprisingly, we found that while monomeric TAK632 promotes dimerization and potently inhibits BRAF dimers in vitro, dimeric TAK inhibitors cannot induce dimers and concomitantly reduce inhibitor potency. This study indicates that the promotion of an αC-in/αC-in BRAF dimer conformation is integral to the ability of TAK632, and likely other Type-II BRAF kinase inhibitors, to inhibit RAF kinases. These studies have implications for the more effective targeting of BRAF dimers with dimeric BRAF inhibitors to address paradoxical activation for more durable treatment of melanoma.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72871" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72871" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Dimeric TAK Inhibitors Have Reduced Potency Relative to Monomeric Inhibitors in Vitro</h3><div class="NLM_p">The pan-RAF inhibitor TAK632 targets wild-type or mutant BRAF and CRAF with IC<sub>50</sub> values in the low nanomolar range.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> We used the crystal structure of BRAF<sup>WT</sup> complexed with TAK632 (accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>) to determine where to link the two TAK632 molecules without compromising TAK632 potency. The TAK632 inhibitor binds both subunits of a BRAF dimer with the αC-helix of both protomers in the αC-in conformation. While the trifluoromethylphenyl moiety of TAK632 is located near the hydrophobic pocket of the binding site, the cyclopropyl amide makes minimal protein contacts, i.e., no interaction between the cyclopropane ring and the protein surface is observed although there is an interaction between the amide N–H and Cys532 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a,b). The amide moiety is exposed to solvent, suggesting it would be an appropriate place to link the monomers, with the caveat that the amide N–H bond is retained in the dimeric molecule (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a). We therefore prepared a series of PEG-linked amide dimers, where n equals the number of PEG units present in the oxidiacetic acid linker of the dimeric structure (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c). Superposition of the BRAF<sup>WT</sup>/TAK632 structure with BRAF<sup>V600E</sup>/Vem-BisAmide-2 (BRAF<sup>V600E</sup> bound to a dimeric vemurafenib inhibitor, accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2">5JT2</a>) suggests that the amide-linking site on TAK632 would produce dimeric TAK inhibitors with similar topology as Vem-BisAmide-2 and related compounds (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>d). The distance between the two TAK632 molecules within a BRAF dimer of the BRAF<sup>V600E</sup>/Vem-BisAmide-2 structure would be predicted to be about 10 Å. On the basis of this docking exercise, we synthesized a series of dimeric TAK-n-TAK molecules where n = 0, 2, 3, 4, and 6 to account for various possible protein dimer orientations (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>e). As a control, we also made two compounds that contain one TAK molecule and parts of the linker to evaluate any adverse effects made by removing the cyclopropane group (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of TAK632 bound BRAF and rationale for linked TAK inhibitors. (a) Structure of BRAF<sup>WT</sup>/TAK632 (accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>), highlighting the exposed cyclopropane ring. (b) Structure of monomeric TAK632 and where it interacts with residue Cys532 of BRAF. (c) Initial scaffold for dimeric TAK inhibitors where n equals the number of ethylene glycol moiety groups present. (d) Alignment of BRAF<sup>WT</sup>/TAK632 (pink and gray) with BRAF<sup>V600E</sup>/Vem-BisAmide-2 structure (blue) (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2">5JT2</a>). (e). Preparation of dimeric TAK-n-TAK structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The requisite dimers were prepared by reaction of the known TAK aminobenzothiazole <b>1</b> with the requisite oxidiacetic acids <b>2</b>–<b>6</b> in the presence of BEP and DIPEA in DMF, in which the tether length was increased by incremental addition of ethylene glycol moieties to generate the TAK-n-TAK series in which n represents the number of ethylene glycol moieties in the linker between the two TAK ligands. The inhibitor potency of each molecule was then evaluated in vitro against both BRAF<sup>WT</sup> and BRAF<sup>V600E</sup> using an ELISA assay that measures the level of phosphorylation of GST-tagged MEK by purified BRAF kinase domain. While all inhibitors showed comparable potency against BRAF<sup>WT</sup> and BRAF<sup>V600E</sup>, their inhibitory potencies were 15–400-fold reduced relative to monomeric TAK632 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a,b). Compounds TAK-2-TAK and TAK-4-TAK showed the greatest potencies of the dimeric inhibitors, with IC<sub>50</sub> values of 132 and 90.2 nM, respectively, against BRAF<sup>WT</sup> and 73.9 and 73.8 nM, respectively, against BRAF<sup>V600E</sup>. The other dimeric TAK inhibitors (TAK-0-TAK, TAK-3-TAK, and TAK-6-TAK) had IC<sub>50</sub> values ranging from 168 to 732 nM. In comparison, monomeric TAK632 had IC<sub>50</sub> values of 3.23 and 4.46 nM against BRAF<sup>WT</sup> and BRAF<sup>V600E</sup>, respectively. These experiments reveal that although the dimeric TAK inhibitors show some dependency on linker length, they are considerably less potent than monomeric TAK632 and therefore likely binding BRAF in a different mode than dimeric Vem-BisAmide-2 and related compounds.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Potency of first-generation dimeric TAK inhibitors. (a) Dose response curves of dimeric TAK inhibitors against BRAF<sup>WT</sup> with TAK632 as a control. Calculated IC<sub>50</sub> values are indicated. The experiments were performed in triplicate with ± SEM shown. The 95% confidence intervals are TAK632 (1.47–7.47 nM), TAK-2-TAK (69.6–249 nM), TAK-4-TAK 48.4–168 nM), TAK-0-TAK (347–832 nM), TAK-3-TAK (351–1.08 μM), and TAK-6-TAK (277–1.94 μM). (b) Dose response curves of dimeric TAK inhibitors against BRAF<sup>V600E</sup> with TAK632 as a control, carried out in triplicate with ± SEM shown. The 95% confidence intervals are TAK632 (2.67–7.45 nM), TAK-2-TAK (47.5–115 nM), TAK-4-TAK (59.7–91.1 nM), TAK-0-TAK (323–549 nM), TAK-3-TAK (128–219 nM), and TAK-6-TAK (199–621 nM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Monomeric TAK Inhibitors Promote BRAF Dimers while Dimeric TAK Inhibitors Do Not</h3><div class="NLM_p">Our previous studies revealed that dimeric vemurafenib inhibitors promoted an inactive “face-to-face” αC-out/αC-out BRAF dimer configuration that differed significantly from the ”side-to-side” active αC-in/αC-out BRAF dimer configuration as bound to monomeric vemurafenib or αC-in/αC-in BRAF dimer configuration not bound to inhibitor.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> To determine if dimeric TAK inhibitors also promoted BRAF dimers, we performed analytical ultracentrifugation (AUC) sedimentation velocity experiments to compare the oligomeric state of BRAF as a function of added TAK inhibitors. We first utilized an R509H BRAF mutant protein that disrupts the side-to-side active dimer interface to promote the formation of BRAF monomers.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> As expected, unliganded BRAF<sup>R509H</sup> migrated with a sedimentation coefficient of ∼3 corresponding to an apparent protein monomer (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a). Surprisingly, however, the addition of a molar excess of dimeric TAK inhibitors did not alter the apparent monomer migration position of BRAF<sup>R509H</sup>, irrespective of linker length (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a–c). The dimeric TAK inhibitors were therefore unable to shift BRAF into an inactive dimeric configuration as anticipated. This differed from chemically linked vemurafenib inhibitors such as Vem-BisAmide-2, which were able to shift BRAF<sup>V600E/R509H</sup> into a dimeric conformation in solution (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00499/suppl_file/jm8b00499_si_001.pdf" class="ext-link">Figure S1</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Sedimentation velocity experiments of dimeric TAK Inhibitors. (a) BRAF<sup>R509H</sup> (10 μM) in the absence and presence of TAK632 and TAK-2-TAK inhibitor at different concentrations. (b) BRAFR<sup>509H</sup> (12 μM) in the absence and presence of TAK632 and TAK-4-TAK inhibitor at different concentrations. (c) BRAF<sup>R509H</sup> (12 μM) in the absence and presence of TAK632, TAK-3-TAK, and TAK-6-TAK inhibitors at 20 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In contrast to the effect of adding dimeric TAK inhibitors to BRAF<sup>R509H</sup>, the addition of a molar excess of monomeric TAK632 to BRAF<sup>R509H</sup> led to the formation of an apparent BRAF<sup>R509H</sup> dimeric species (sedimentation coefficient of ∼4, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a–c). While the literature demonstrates that TAK632 can induce dimers at lower concentrations than vemurafenib,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> the fact that TAK632 can induce dimers in vitro despite a R509H point mutation that is known to disrupt dimers was unexpected. These studies demonstrate that monomeric TAK632 actively promotes the formation of BRAF dimers.</div><div class="NLM_p">To determine whether higher concentrations of the dimeric TAK inhibitors are able to shift BRAF<sup>R509H</sup> into a dimeric configuration, we titrated 20 μM protein with 25–200 μM TAK-4-TAK and found that even the highest concentration of dimeric inhibitor was unable to fully shift the protein into a dimeric configuration, although at the highest concentration of TAK-4-TAK (200 μM), BRAF<sup>R509H</sup> gives a more broad sedimentation curve, indicating that at these high concentrations the protein/inhibitor complex begins to shift toward a dimeric species (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a). Consistent with the results above, we also demonstrated that BRAF<sup>WT</sup> and BRAF<sup>V600E</sup> form dimeric species in the presence of monomeric TAK632 and form either monomers or mixed monomer/dimer populations in the presence of dimeric TAK inhibitors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b,c). To confirm these findings, we ran sedimentation equilibrium experiments of BRAF<sup>R509H</sup> in the absence and presence of monomeric TAK632 and dimeric TAK inhibitors. Log plots of the data are shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>d, where the slope of the line is proportional to the estimated molecular weight of the species in solution. Sedimentation equilibrium curves and residuals are shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00499/suppl_file/jm8b00499_si_001.pdf" class="ext-link">Figure S2</a>. BRAF<sup>R509H</sup>/TAK632 gave an ideal molecular weight fit of ∼69 kDa, aligning with the simulated dimer of ∼70 kDa. In contrast, BRAF<sup>R509H</sup>/TAK-4-TAK gave an ideal molecular weight fit of ∼40 kDa, aligning with the simulated monomer of ∼35 kDa. BRAF<sup>R509H</sup> without inhibitor also aligns with the simulated monomer, giving an ideal molecular weight fit of ∼36 kDa. Taken together, the observation that monomeric TAK632 inhibitors promote the formation of BRAF dimers and that the dimeric TAK inhibitors cannot, coupled with our earlier findings that monomeric TAK632 is much more potent than TAK dimers for BRAF inhibition (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), leads to the conclusion that TAK632 promotes inhibition of BRAF through the induction of inhibited dimers.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Sedimentation velocity and sedimentation equilibrium experiments of dimeric TAK Inhibitors. (a) BRAF<sup>R509H</sup> (20 μM) in the absence and presence of TAK632 and TAK-4-TAK inhibitor at different concentrations. (b) BRAF<sup>WT</sup> (10 μM) in the absence and presence of TAK632 and TAK-2-TAK. (c) BRAF<sup>V600E</sup> (10 μM) in the absence and presence of TAK632 and TAK-2-TAK and TAK-4-TAK inhibitors at different concentrations. (d) Log plots of sedimentation equilibrium experiments showing theoretical monomer (purple) and theoretical dimer (blue) slopes of BRAF compared to BRAF<sup>R509H</sup> in the absence and presence of TAK632 and dimeric TAK-4-TAK at a 2:1 molar ratio of inhibitor to protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> The Dimeric Nature of the Linked TAK Inhibitors Is Required to Reduce Inhibitor Potency and to Promote BRAF Monomers</h3><div class="NLM_p">To determine whether the two TAK632 ligands or the glycol linker was responsible for promoting the formation of the BRAF monomers, we prepared two compounds with the linker intact and only one TAK632 molecule (TAK-L and TAK-L-C, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). TAK-L, included the PEG portion of the linker, while TAK-L-C included the PEG and the 1,3-thiazole-2-amide moiety of the second TAK632 molecule as a cap. Coupling of the TAK molecule <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>e) with commercially available 2-(2-methoxyethoxy) acetic acid <b>12</b> led to the formation of <b>13 TAK-L</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00499/suppl_file/jm8b00499_si_001.pdf" class="ext-link">Supporting Information</a> for details). The TAK-L-C <b>14</b> was prepared from 3,6,9-trioxaundecandioic acid <b>3</b>, first by anhydride formation with DCC, followed by ring opening with 2-aminothiazole and coupling of the TAK molecule <b>1</b> with the resulting monoacid intermediate to give <b>14</b> (TAK-L-C). Both molecules were evaluated in ELISA kinase activity assays and sedimentation velocity experiments to assess the effect of these two linker regions on TAK potency and the ability to promote BRAF dimers, respectively. Dose response kinase inhibition experiments demonstrated that TAK-L had similar inhibitor potency to TAK632, with IC<sub>50</sub> values of 5.75 and 7.11 nM, respectively, and TAK-L-C showed only about a 4-fold reduced potency (20.3 nM) relative to TAK632 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). In contrast, the dimeric TAK inhibitors, TAK-2-TAK and TAK-4-TAK, showed about a 12-fold reduction in potency (>85 nM) relative to TAK632 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). These data demonstrate that the second TAK632 ligand in the dimeric TAK inhibitor plays a significant role in the reduced potency of the dimeric TAK inhibitors relative to monomeric TAK632. These results also indicate that linker placement and removal of the cyclopropane group does not significantly hinder the ability of the dimeric inhibitors to inhibit BRAF relative to monomeric TAK632.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Biochemical and biophysical properties of TAK-linker compounds. (a) Preparation of monomeric TAK control compounds, TAK-L (TAK with linker) and TAK-L-C (TAK with linker and cap). (b) Dose response curves of TAK control compounds along with dimeric TAK-2-TAK and TAK-4-TAK and TAK632 against BRAF<sup>WT</sup>. Calculated IC<sub>50</sub> values are indicated. The experiments are performed in duplicate with ± SEM shown. 95% confidence intervals are TAK-L (3.33–9.91 nM), TAK-L-C (10.3–40.2 nM), TAK-2-TAK (50.2–151 nM), TAK-4-TAK (56.7–129 nM), and TAK632 (3.32–15.2 nM). (c) Sedimentation velocity experiments with BRAF<sup>R509H</sup> (15 μM) in the presence of TAK-L, TAK-L-C, and TAK-2-TAK at 20 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Sedimentation velocity experiments with BRAF<sup>R509H</sup> in the presence of monomeric TAK-L and TAK-L-C or the dimeric TAK-2-TAK reveal that the TAK inhibitors containing linkers and a single TAK632 ligand promoted the formation of protein dimers, while TAK-2-TAK could not alter the oligomerization state upon binding (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c), as previously shown (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a). These data demonstrate that the second TAK632 ligand in the dimeric TAK inhibitor plays a driving role in preventing the formation of inhibited BRAF dimers, which appears to be correlated with the reduced potency of the dimeric TAK inhibitors relative to monomeric TAK632.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Dimeric TAK Inhibitors Display Distinct BRAF Properties</h3><div class="NLM_p">To further explore the mechanism by which dimeric TAK inhibitors bind BRAF, we performed a limited proteolysis experiment in which trypsin was added to BRAF<sup>WT</sup> in the presence and absence of TAK632, TAK-2-TAK, TAK-L-C, and vemurafenib (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). When no ligand is present (lane 1), the major digested band (species A) is very close in size to undigested BRAF, with the appearance of two smaller minor bands (species B and C). In the presence of TAK632 and TAK-L-C (lanes 2 and 3, respectively), BRAF<sup>WT</sup> species A becomes a minor band, while species B and C become major bands. In contrast, in the presence of TAK-2-TAK (lane 4), BRAF<sup>WT</sup> had a digestion pattern resembling that of unliganded BRAF<sup>WT</sup>, producing BRAF<sup>WT</sup> species A as a major band but with slightly larger amounts of species B and C. In the presence of vemurafenib (lane 5), BRAF<sup>WT</sup> produces species A as the major band, with negligible amounts of species B and C. These results demonstrate that in the presence of the dimeric TAK-2-TAK, BRAF has a digestion pattern that is somewhere in between BRAF<sup>WT</sup> alone and monomeric TAK632/TAK-L-C. These observations indicate that dimeric TAK inhibitors cannot fully promote a conformation allowing for degradation to species B and C, whereas monomeric TAK molecules can.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Determination of dimeric TAK inhibitor binding modes to BRAF. (a) Limited proteolysis experiment of BRAF<sup>WT</sup> in the presence and absence of 200 μM inhibitors after exposure to trypsin for 30 min (lanes 1–5), and lane 6 shows BRAF<sup>WT</sup> without ligand or trypsin. (b) Differential scanning calorimetry (DSC) experiments in which BRAF<sup>WT</sup> is heated in the presence and absence of inhibitors ranging in concentration from 25 to 250 μM. Melting temperatures are as follows: 125 μM TAK632, 68.74 °C; 125 μM TAK-L-C, 63.29 °C; 75 μM TAK-2-TAK, 38.37 °C, 58.65 °C; 125 μM TAK-2-TAK, 38.72 °C, 59.6 °C; 250 μM TAK-2-TAK, 40.08 °C, 62.64 °C; no ligand, 37.84 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To further dissect the mode of dimeric TAK inhibitor binding to BRAF, we performed Differential Scanning Calorimetry (DSC) experiments in which BRAF<sup>WT</sup> protein (37 μM) was heated in the presence and absence of ligands to determine melting temperatures (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b). When no ligand is present (black), we observe a single melting temperature of 37.84 °C, which we interpret as melting of a BRAF<sup>WT</sup> monomer. In the presence of TAK632 or TAK-L-C (125 μM) (violet and cyan, respectively), we observe single melting temperatures of 68.74 and 63.29 °C, respectively, which we interpret as melting of BRAF<sup>WT</sup> dimers bound to monomeric TAK inhibitors. In contrast, in the presence of TAK-2-TAK (125 μM) (pink), two broad melting temperatures are observed of 38.72 and 59.6 °C, and titration of TAK-2-TAK between 75 and 250 μM produces more of the higher melting temperature species at the expense of the lower melting temperature species. We interpret this observation to indicate that while dimeric TAK inhibitors do have a capacity to promote BRAF dimers at high concentration of dimeric inhibitor, they do so significantly more poorly than monomeric TAK632. Taken together, both the limited proteolysis (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a) and DSC (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b) studies reveal that dimeric TAK inhibitors promote BRAF species in solution that act as a combination of both unbound BRAF and BRAF bound to monomeric TAK, indicating that the dimeric TAK inhibitors cannot fully stabilize the dimeric TAK632-mediated BRAF configuration.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Trp450, Arg506, and the αC-Helix Play Significant Roles in Dimer Formation via TAK Binding</h3><div class="NLM_p">Given our surprising finding that the monomeric TAK632 inhibitor promotes formation of αC-in/αC-in BRAF dimers, even in the presence of the R509H dimerization-defective mutant, we set out to better understand the nature of the BRAF dimer that is stabilized by monomeric TAK632. R509 is able to stabilize the active “side-to-side” αC-in/αC-in configuration by making hydrogen bond interactions with backbone carbonyls of T508 and R506.<a onclick="showRef(event, 'ref11 ref19'); return false;" href="javascript:void(0);" class="ref ref11 ref19">(11,19)</a> To assess what additional changes are necessary to facilitate TAK632-induced dimerization, we superimposed different subunits of the BRAF<sup>WT</sup>/TAK632 (accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> BRAF<sup>V600E</sup>/AZ628 (accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R">4G9R</a>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and BRAF<sup>R509H</sup>/AZ628 (accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> crystal structures. AZ628 is another type II, αC-in inhibitor, and was also shown to be able to induce dimerization in the presence of an R509H mutation, however at a higher concentration.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> This superposition revealed that the inhibitor complexes with BRAF<sup>WT</sup> and BRAF<sup>V600E</sup> contain highly super imposable αC-in/αC-in configurations (RMSD of 0.596 Å<sup>2</sup> for BRAF<sup>WT</sup>/TAK αC segments and 0.463 Å<sup>2</sup> for BRAF<sup>V600E</sup>/AZ628 αC segments), while the BRAF<sup>R509H</sup>/AZ628 structure contains more variable αC-in configurations (RMSD of 1.713 Å<sup>2</sup> for corresponding αC segments) where one of the αC segments orients further away from the αC-out configuration while the other moves closer toward the αC-out configuration (as seen in the BRAF<sup>V600E</sup>/Vem complex, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>a). This observation suggests that while the R509H mutation destabilizes the active αC-in/αC-in dimer and favors an inactive, αC-out configuration, type II inhibitor binding is able to compensate for the destabilizing R509H mutation to further strengthen the dimer by biasing the kinase toward an αC-in/αC-in dimer configuration.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. BRAF<sup>R509H</sup> dimer interface via TAK632 binding. (a) Overlay of BRAF<sup>WT</sup>/TAK632 (light pink and magenta), BRAF<sup>V600E</sup>/AZ628 (light gray and dark gray), BRAF<sup>R509H</sup>/AZ628 (blue and teal), and BRAF<sup>V600E</sup>/vemurafenib (yellow) structures, highlighting the shift within the αC-in position. Different subunits of the crystal structures are denoted with subscript 1 and 2, respectively. (b) Overlay of BRAF<sup>WT</sup>/TAK632 (light pink, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>), BRAF<sup>V600E</sup>/AZ628 (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R">4G9R</a>), and BRAF<sup>R509H</sup>/AZ628 (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>), highlighting a shift in the W450 residue in the BRAF<sup>R509H</sup> structure. (c) Crystal structure of BRAF<sup>R509H</sup> bound to AZ628 demonstrates that W450 forms π-stacking interactions with His509. (d) Residue D448 accompanies the shift in the W450 residue, hydrogen bonding with the other static W450. (e) R506 residues in both subunits of BRAF<sup>WT</sup>/TAK632 (light pink and magenta), BRAF<sup>V600E</sup>/AZ628 (light gray and dark gray), and BRAF<sup>R509H</sup>/AZ628 (blue and teal) aligned with one subunit of BRAF<sup>V600E</sup>/vemurafenib (yellow), demonstrating “in” and “out” positions of R506. (f). W450 lies within close proximity of R506 and the W450 in BRAF<sup>R509H</sup>/AZ628 shifts closer to R506.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In comparing the three crystal structures described above, we noted that W450 participates in van der Waals interactions with the aliphatic region of R509 but that W450 adopts a distinct conformation in one of the protomers of the BRAF<sup>R509H</sup>/AZ628 structure, which appears to be facilitated by a π-stacking interaction with the R509H mutation of the other protomer (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>b,c) and accompanied by a movement of D448 to hydrogen bond to W450 of the opposing subunit (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>d). Reinforcing the importance of W450 for active BRAF dimer formation, a W450A mutation was previously demonstrated to impair transactivation in cells.<a onclick="showRef(event, 'ref10 ref25'); return false;" href="javascript:void(0);" class="ref ref10 ref25">(10,25)</a> These results indicate that W450 plays a critical role in the ability of TAK632 (and possibly other type II αC-in inhibitors such as AZ628) to induce dimerization.</div><div class="NLM_p">R506 is another residue previously noted to play a significant role in inhibitor-induced dimerization based on the unique conformations that it adopts in cocrystal structures of BRAF bound to αC-in (ie. AZ628) and αC-out (i.e., vemurafenib) inhibitors.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Specifically, R506 adopts an “in” position in the BRAF<sup>R509H</sup>/AZ628 structure but adopts an “out” position in BRAF<sup>V600E</sup>/vemurafenib (Vem) (3OG7, yellow) structures (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>e). R506 lies close to W450, and the distinct W450 shift present in the one BRAF<sup>R509H</sup>/AZ628 protomer that shifts closer to the R506 “out” conformation further supports the integral role of R506 in dimerization (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>f).</div><div class="NLM_p">To evaluate the effect of W450 and R506 on TAK-induced dimerization, we performed sedimentation velocity experiments with BRAF<sup>W450A</sup>, BRAF<sup>R506A</sup>, BRAF<sup>W450A/R509H</sup>, BRAF<sup>R506A/R509H</sup>, and BRAF<sup>R506A/W450A/R509H</sup> mutants alone and in the presence of TAK632 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a,b). We found that TAK632 promotes the complete dimerization of BRAF<sup>R506A</sup> and BRAF<sup>W450A</sup>, but TAK632 with the double mutants of BRAF<sup>R509H/W450A</sup> and BRAF<sup>R506A/R509H</sup> showed a peak that is in between that of a monomer and a dimer. The peaks also appear to be slightly broader than those of species that sediment as complete monomers or dimers. We hypothesize that these mutants are able to disrupt TAK632-induced dimerization, however not completely, thus giving a mixed monomer/dimer peak. The triple mutant BRAF<sup>R509H/R506A/W450A</sup> in the presence of TAK632 sediments less broadly and more closely to that of a monomer peak, indicating that the combination of all three mutations disrupts TAK632 induced dimerization more than any of the individual mutations. We confirmed these results with sedimentation equilibrium measurements (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>c), where BRAF<sup>R509H/R506A</sup> gives an estimated ideal molecular weight of 58000 kDa while BRAF<sup>R509H/W450A</sup> gives an estimated molecular weight of 57000 kDa (raw curves and residuals are shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00499/suppl_file/jm8b00499_si_001.pdf" class="ext-link">Figures S2 and S3</a>.) BRAF<sup>R509H/R506A/W450A</sup> leads to the smallest molecular weight of the mutants, 47000 kDa, indicating that while TAK632 binding does still induce dimerization slightly, the ability to do so is dramatically decreased due to mutation of the residues that mediate dimerization. While each of these mutants alone is not enough to prevent TAK632-induced dimerization, combining them causes conformational changes in the active dimer and combining all three prevents the majority of molecules in solution from forming dimers. Taken together, these studies indicate that R509, W450, and R506 play important roles in facilitating the active αC-in/αC-in BRAF dimer as well as TAK632-induced dimerization. The observation that TAK632 still efficiently promotes dimers of the single BRAF<sup>W450A</sup>, BRAF<sup>R506A</sup>, and BRAF<sup>R509H</sup> mutants but not the BRAF<sup>R509H/R506A/W450A</sup> mutant suggests that all three residues play a coordinated role in “side-to-side” αC-in/αC-in configuration dimerization, which is further reinforced by TAK632 binding.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Sedimentation velocity experiments of dimerization mutants and αC-in/αC-out inhibitors. (a) Sedimentation velocity experiments of BRAF<sup>R509H</sup>, BRAF<sup>R506A</sup>, and BRAF<sup>W450A</sup> in the absence and presence of TAK632 at 15–25 μM. (b) Sedimentation velocity experiments of BRAF<sup>R509H</sup>, BRAF<sup>R506A/R509H</sup>, BRAF<sup>W450A/R509H</sup>, and BRAF<sup>R506A/W450A/R509H</sup> in the absence and presence of TAK at 25 μM. (c) Sedimentation velocity experiments of BRAF<sup>R509H</sup> without inhibitor and with 20 μM of both TAK632 and sorafenib. (d) Sedimentation velocity experiments of BRAF<sup>WT</sup> and BRAF<sup>V600E</sup> with 15 μM vemurafenib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Type II αC-in and Type I αC-out Inhibitors Promote BRAF Dimers and Monomers, Respectively</h3><div class="NLM_p last">To assess whether other type II αC-in inhibitors are able to induce BRAF dimerization in solution, we performed sedimentation velocity experiments with sorafenib, another well-known type II, αC-in inhibitor.<a onclick="showRef(event, 'ref18 ref26'); return false;" href="javascript:void(0);" class="ref ref18 ref26">(18,26)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>d, sorafenib behaves similarly to TAK632, promoting dimerization despite the R509H mutation, further reinforcing the finding that type II αC-in inhibitors function by stabilizing the active “side-to-side” αC-in/αC-in BRAF dimer configuration. To explore the effects of a type I αC-out inhibitor, we used vemurafenib as a model αC-out inhibitor. We found that BRAF<sup>WT</sup> monomers were stabilized and BRAF<sup>V600E</sup> dimers were disrupted upon addition of vemurafenib (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>e). Taken together, type II αC-in inhibitors appear to promote BRAF dimerization, while type I αC-out inhibitors such as vemurafenib promote a disruption of the BRAF dimer. TAK632 therefore relies on its ability to induce dimerization for effective inhibition, unlike αC-out inhibitors such as vemurafenib.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54873" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54873" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this study, we demonstrate that the induction of an αC-in/αC-in configuration is integral for potent TAK632 inhibition. The mutational and analytical ultracentrifugation analyses further highlight the importance of R509, W450, R506, and likely also D448 in mediating this dimeric BRAF conformation. The analysis that we present here with the other type II αC-in inhibitors AZ628 and sorafenib suggests that these findings extend to the broader family of αC-in inhibitors. Coupled with the potent BRAF inhibitory activity and absence of paradoxical activation activity of such inhibitors, these findings support the conclusion that TAK632 and related inhibitors promote inhibition of BRAF through the induction of inhibited dimers.</div><div class="NLM_p">While previous studies have highlighted the importance of R509 in stabilizing αC-in/αC-in BRAF dimers, we have further analyzed the molecular basis of stabilization of this dimeric BRAF configuration, concomitant with positioning the C-helix in the αC-in configuration. We demonstrate that W450, R506, and likely also D448 play important roles in this activity. Other studies have also proposed the importance of R506 in mediating BRAF dimer formation, and we have demonstrated that it plays a similar role in inhibitor-induced dimerization as W450.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">In contrast to monomeric TAK632, the less potent dimeric TAK inhibitors appear unable to promote the αC-in/αC-in dimeric configuration. This leads to BRAF monomers being the predominant species, while monomeric TAK632 is able to induce RAF dimerization upon binding. Comparison of the BRAF activities and multimerization states of BRAF complexes with dimeric TAK inhibitors and monomeric TAK632 inhibitors with attached linkers reveals that the second TAK632 molecule of the dimeric TAK inhibitors plays a particularly important role in the reduced BRAF kinase activity and promotion of the monomeric BRAF state. The control inhibitors TAK-L and TAK-L-C also demonstrate that linker placement and removal of the cyclopropane group does not affect active site binding, indicating a more complex mechanism. Although our data implies that the reduced inhibitor activity of the dimeric TAK inhibitors is correlated with their inability to promote BRAF dimers, the molecular basis for how the second TAK632 ligand of the dimeric TAK inhibitor destabilizes the BRAF dimer configuration that is promoted by TAK632 is unclear. Limited proteolysis and DSC experiments suggest that while dimeric TAK inhibitors can mediate a BRAF configuration that is similar to that of TAK632-bound BRAF, their affinities for these sites are notably decreased. We propose that dimeric TAK inhibitors have significantly reduced affinities for BRAF because they are unable to assume stable dimeric BRAF configurations. We have extensively attempted crystallization of these molecules with BRAF<sup>WT</sup> and were unsuccessful, and we hypothesize that this is due to the second molecule of TAK binding loosely, making the species in solution heterogeneous and dynamic, hindering any ability to crystallize.</div><div class="NLM_p">In previous studies, we demonstrated that dimeric vemurafenib inhibitors promote inactive BRAF<sup>V600E</sup>/BRAF<sup>V600E</sup> homodimeric conformations with both protomers containing αC-out conformations. These dimeric inhibitors also displayed improved potency and selectivity for BRAF<sup>V600E</sup> in vitro.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Interestingly, we found that dimeric vemurafenib inhibitors were able to induce the same, face-to-face αC-out/αC-out BRAF dimeric configurations, independent of linker length. This was not the case with dimeric TAK inhibitors in this study, in which we found that the dimeric TAK inhibitors cannot promote BRAF dimers, resulting in reduced potency relative to monomeric TAK632. To understand the molecular basis for why dimeric TAK inhibitors are unable to induce the same dimer face-to-face αC-out/αC-out BRAF dimeric configuration promoted by dimeric vemurafenib inhibitors, we overlaid individual BRAF molecules bound to TAK632 with the “face-to-face” conformation of BRAF bound to the dimeric Vem-BisAmide-2 inhibitor (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a). Although this modeling exercise does not reveal any steric clashes between the BRAF molecules in the modeled TAK632-bound inactive dimeric configuration, we observe different configurations of the Vem-BisAmide-2 and TAK632-bound BRAF proteins that could destabilize TAK632-bound BRAF dimers in this BRAF dimer configuration (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>b). Specifically, we note that while Vem-BisAmide-2 binding favors the activation segment to flip outward into an active conformation (cyan), the activation segment of BRAF bound to TAK632 molecules favors an inactive, inward activation segment conformation (magenta). While the activation segment is mostly unresolved in the BRAF/TAK632 structure, this dynamic region could generate steric clashes with the activation segment of another BRAF molecule, making the “face-to-face” dimeric conformation energetically unfavorable. We therefore propose that it is not possible for dimeric TAK inhibitors to induce an inactive, “off-state” BRAF dimer configuration, and this is likely true with other αC-in inhibitors such as sorafenib and AZ628. Instead, we hypothesize that pan-RAF inhibitors that favor the αC-out conformation will be more amenable to the preparation of dimeric inhibitors with improved BRAF potency and with the ability to counteract transactivation of RAF<sup>WT</sup>/RAF<sup>WT</sup> homodimers and RAF<sup>WT</sup>/BRAF<sup>V600E</sup> heterodimers in melanoma and other BRAF-associated cancers. Interestingly, the pan-RAF inhibitors reported to date all appear to stabilize the active αC-in conformation. We propose that a solution to this will be to prepare dimeric BRAF inhibitors with highly potent BRAF<sup>V600E</sup>-specific αC-out promoting inhibitors that still retain appreciable affinity for BRAF<sup>WT</sup>. Such inhibitors could be molecules such as dabrafenib and BI 882370, which inhibit BRAF<sup>WT</sup> and CRAF<sup>WT</sup> with potencies similar to pan RAF inhibitors such as TAK632.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Another possibility is a purinylpyridinylamino-based BRAF inhibitor that is BRAF<sup>V600E</sup>-specific but binds two molecules of a BRAF<sup>WT</sup> side-to-side dimer with two αC-out configurations.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Taken together, these studies highlight the importance of understanding the impact of BRAF inhibitors on kinase dimerization to effectively target RAF<sup>WT</sup>/RAF<sup>WT</sup> homodimers and RAF<sup>WT</sup>/BRAF<sup>V600E</sup> heterodimers with dimeric pan-RAF inhibitors to target paradoxical activation for more durable treatment of melanoma.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Superposition of BRAF<sup>V600E</sup>/Vem-BisAmide-2 with BRAFWT/TAK632. (a) Overlay of BRAF<sup>WT</sup> cocrystallized with TAK632 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>) overlaid with the αC-out/αC-out “face-to-face” dimer induced by Vem-BisAmide-2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2">5JT2</a>). (b) Comparison of activation segment of BRAF<sup>V600E</sup> bound to Vem-BisAmide-2 in an active conformation (cyan) and the activation segment of BRAF<sup>WT</sup> bound to TAK632 in an inactive conformation (magenta), protruding into the other molecule of the “face-to-face” dimer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">1.  Plasmids</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Proteins Used for Analytical Ultracentrifugation Sedimentation Velocity Experiments</h4><div class="NLM_p last">DNA encoding the BRAF kinase domain residues 448–723 containing 16 solubilizing mutations (I543A, I544S, I551 K, Q562R, L588N, K630S, F667E, Y673S, A688R, L706S, Q709R, S713E, L716E, S720E, P722S, and K723G) was ordered from Epoch Biolabs and cloned into a Pet28a(+) vector encoding an N-terminal 6XHis Tag and a thrombin cleavage site between the protein and the tag. This construct was used as a template to create His-tagged BRAF<sup>V600E</sup>, BRAF<sup>R509H</sup>, BRAF<sup>R506A</sup>, BRAF<sup>W450A</sup>, BRAF<sup>W450A/R509H</sup>, BRAF<sup>R506A,R509H</sup>, and BRAF<sup>R506A,R509H,W450A</sup> mutants (each harboring the 16 stabilizing mutations noted above). These proteins were used in analytical ultracentrifugation sedimentation velocity experiments.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Proteins Used for Kinase Inhibition Assays</h4><div class="NLM_p last">DNA encoding the BRAF kinase domain residues 442–724 was used as a template and cloned into a Pfastbac dual vector with mouse p50<sup>cdc37</sup> full length as an expression chaperone for protein expression in baculovirus infected Sf9 insect cells. An N-terminal 6X-His tag was inserted into the plasmid, and this plasmid was used as a template to create mutant BRAF<sup>V600E</sup>. Full length human MEK1 with an N-terminal GST fusion tag and a C-terminal His tag in a pGex-3t vector was provided by Dr. Michael Olson (Beatson Institute for Cancer Research, Glasgow, UK) and was used as the substrate for the in vitro kinase assays.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.  Protein Purification</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Proteins Used for Analytical Ultracentrifugation Sedimentation Velocity, Limited Proteolysis, and Differential Scanning Calorimetry Experiments</h4><div class="NLM_p last">His-tagged BRAF proteins were produced as previously described.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In brief, proteins were expressed in (DE3)RIL bacterial expression cells at 37 °C and induced with 1 mM IPTG overnight at 18 °C, spun down the next day, and lysed in lysis buffer (50 mM potassium phosphate pH 7.0, 250 mM NaCl) with 1 mM PMSF and DNaseI. The lysate was spun down at 19000 rpm for 20 min, and the supernatant was added to 7 mL of TALON metal affinity resin (Takara) and left to incubate at 4 °C for 1 h. The supernatant was eluted via gravity column, and the resin was washed with 1 L of lysis buffer with 10 mM imidazole. The BRAF proteins were eluted with lysis buffer supplemented with 250 mM imidazole. Protein was dialyzed into dialysis buffer (50 mM potassium phosphate pH 7.0, 5 mM EDTA pH 7.5, 1 mM DTT (dithiothreitol)) overnight and then applied to a 5 mL SP Sepherose cation exchange column followed by washing in dialysis buffer and elution in 50 mM potassium phosphate pH 7.0, 1 M NaCl, and 1 mM DTT. Peak fractions were run on an SDS-PAGE gel, pooled, concentrated, and applied to a Superdex S200 gel filtration column in a final buffer of 20 mM HEPES pH 7.0, 150 mM NaCl, 5% glycerol, and 10 mM DTT. Protein was concentrated to 5–10 mg/mL, flash frozen in liquid nitrogen, and stored in −80 °C freezer for future use.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Proteins Used for Kinase Inhibition Assays</h4><div class="NLM_p">BRAF<sup>WT</sup> and BRAF<sup>V600E</sup> were overproduced as N-terminally His-tagged proteins in insect cells essentially as previously described.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Briefly, protein constructs were coexpressed with p50<sup>cdc37</sup>, pelleted, suspended in lysis buffer 2 (25 mM Tris pH 8.0, 250 mM NaCl, 5 mM imidazole, and 10% glycerol) treated with complete EDTA-free protease inhibitor cocktail tablets (Roche) and DNaseI, lysed, centrifuged at 19000 rpm for 30 min, added to TALON metal affinity resin, and incubated for 1 h at 4 °C. The protein on the resin was washed extensively with 1 L of lysis buffer 2 and eluted with 25 mM Tris pH 7.5, 250 mM NaCl, 250 mM imidazole, and 10% glycerol. The protein was diluted into a low salt buffer containing 25 mM Tris pH 8.0, 1 mM EDTA, and 1 mM DTT, run on an SP Sepharose cation exchange column, and eluted with a salt gradient from 50 mM NaCl to 1 M NaCl. Peak fractions were run on an SDS-PAGE gel, and fractions containing protein were pooled, concentrated, and applied to a Superdex S200 gel filtration column and stored in a final buffer of 25 mM Tris pH 8.0, 300 mM NaCl, 1 mM DTT, and 10% glycerol. Protein was concentrated to ∼0.5 mg/mL and flash frozen in liquid nitrogen and stored for later use in a −80 °C freezer.</div><div class="NLM_p last">GST-MEK1 fusion protein used as a substrate in ELISA assays was prepared essentially as described previously.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Briefly, the protein was expressed in (DE3) RIL cells at 37 °C and induced with 0.5 mM IPTG at 15 °C overnight. The cells were harvested and resuspended in lysis buffer 3 (20 mM HEPES at pH 7.0, 500 mM NaCl, 10 mM BME, 10 mM imidazole, and 5% glycerol) supplemented with 1 mM PMSF and DNaseI. The lysate was sonicated and spun down at 19000 rpm for 30 min, and the supernatant was added to Ni-NTA resin and incubated for 1 h at 4 °C. The resin was washed extensively with lysis buffer 3 with 20 mM imidazole instead of 10 mM and eluted with lysis buffer 3 supplemented with 250 mM imidazole. Eluted protein was concentrated and loaded onto a Superdex S200 16/60 gel filtration column into a final buffer of 20 mM HEPES pH 7.0, 150 mM NaCl, 10 mM BME, and 5% glycerol. The protein eluted off the sizing column in two separate populations, and the second peak was collected, concentrated to ∼20 mg/mL, and flash frozen in liquid nitrogen and stored in −80 °C freezer for future use.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> In Vitro Kinase Assay</h4><div class="NLM_p last">Compound inhibition of BRAF<sup>WT</sup> and BRAF<sup>V600E</sup> were performed using an ELISA assay described previously.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Briefly, GST-MEK fusion protein was diluted 3:1000 in Tris-buffered saline (25 mM Tris pH 7.5, 140 mM NaCl) treated with 0.05% Tween-20 (TBST), and diluted MEK was added to each well of a glutathione coated 96-well plate (Pierce no. 15240) and incubated at room temp for 1 h with shaking. BRAF was diluted from frozen stocks (1:500 dilution for BRAF<sup>WT</sup> and 1:1000 dilution for BRAF<sup>V600E</sup>) in 50 mM HEPES pH 7.0 and 50 mM NaCl. Then 2 μL of desired concentration of inhibitor was added to 100 μL of diluted BRAF in a 96 well “V” bottom plate (Corning no. 2897) and the inhibitor/protein mixture was incubated for 1 h at room temp. Glutathione plates were washed extensively with TBST, and the protein–inhibitor mixture was added to the plate with a 100 μM final concentration of ATP in a buffer containing 50 mM HEPES pH 7.0, 200 mM NaCl, and 20 mM MgCl<sub>2</sub>. The plate was incubated at 37 °C for 30 min. The reaction was washed from the plate, and the plate was again washed with TBST. A 1:8000 dilution of primary antibody (p-MEK1/2 (S217/S221) rabbit antibody (cell signaling)) in TBST treated with 0.5% BSA was added to the plate and incubated for 1 h with shaking. The plate was then treated with multiple TBST washes and then incubated with a 1:10000 dilution of secondary antibody (goat antirabbit IgG (H+L)-HRP (BioRad)) in TBST treated with 0.5% BSA for 1 h with shaking. The plate was washed extensively with TBST, and Supersignal ELISA Pico chemiluminescent substrate (Pierce no. 37069) was added. The plate was read on a Promega GloMAX 96 microplate luminometer. Each curve was repeated in duplicate or triplicate, normalized using GraphPad Prism by selecting the largest value as the maximum and the lowest value as the minimum, and used to calculate IC<sub>50</sub> values by using a log (inhibitor) vs response fit on Prism 5.0 (GraphPad). Error bars are indicative of the SEM of each point, and 95% confidence intervals are listed in the figure legends as calculated by GraphPad Prism.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">3.  Analytical Ultracentrifugation (AUC)</h3><div class="NLM_p">Sedimentation velocity AUC was performed with a Beckman Optima XL-I at 42000 rpm. Data were obtained over a period of ∼15 h of centrifugation at 20 °C by monitoring absorbance. Previously frozen stocks of BRAF and all corresponding mutations (R509H, V600E, R506A, W450A, R506A/R509H, R509H/W450A, and R506A/R509H/W450A) were thawed and diluted to ∼10–20 μM depending on the experiment in AUC buffer (25 mM Tris pH 7.5, 150 mM NaCl), and inhibitor was added to the desired final concentration by adding 20 μL of stock concentration of inhibitor in 100% DMSO to 430 μL of protein to give a final DMSO concentration of 4.44%. Samples run without inhibitor had 20 μL of DMSO added to give the same 4.44% DMSO concentration as a control. Data were analyzed using SEDFIT to calculate a continuous c(s) distribution with a frictional coefficient set to 1.20, and data were graphed using GraphPad Prism.</div><div class="NLM_p last">Sedimentation equilibrium AUC was performed with the same Beckman Optima XL-I at three speeds (9000, 12000, and 18000 rpm) at three different concentrations (20, 10, and 5 μM) of BRAF<sup>R509H</sup> supplemented with a 2:1 molar ratio of inhibitor to protein at each concentration. AUC buffer from sedimentation velocity experiments were used in sedimentation equilibrium experiments. Data were analyzed using heteroanalysis to calculate an ideal fit molecular weight of the species, and log plots of the data were subsequently graphed using GraphPad Prism. Log plots were calculated using the 12000 rpm data of each set. Ideal monomer and dimer fits were calculated using heteroanalysis. Raw data curves and residuals are shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00499/suppl_file/jm8b00499_si_001.pdf" class="ext-link">Figures S2 and S3</a>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.  Limited Proteolysis</h3><div class="NLM_p last">First, 98 μL of 29 μM BRAF<sup>WT</sup> in LP buffer (20 mM HEPES pH 7.0, 150 mM NaCl) were added to eppendorf tubes with 1 μL of 0.5 mg/mL trypsin (Sigma-Aldrich, T1426-50MG) and 2 μL of either DMSO or inhibitor dissolved in 100% DMSO to give a final inhibitor concentration of 200 μM. Inhibitors TAK632, TAK-4-TAK, TAK-L-C, and vemurafenib were then tested, as well as a control in which no trypsin was added. After 30 min of protease treatment, 20 μL of the reaction mixture was removed and added to 5 μL of 5× SDS loading buffer, boiled and run on a 13.5% acrylimide gel using SDS-PAGE, followed by staining using Coomassie blue.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">5.  Differential Scanning Calorimetry (DSC)</h3><div class="NLM_p last">BRAF<sup>WT</sup> was diluted to a final concentration of 37 μM in DSC buffer (20 mM HEPES pH 7.0, 150 mM NaCl). Then 50 μL of either DMSO or inhibitor dissolved in 100% DMSO was added to 450 μL of BRAF<sup>WT</sup> and degassed for 3 min. The protein/inhibitor or protein/DMSO mixture was then added to a MicroCal VP-Capillary DSC (Malvern) and blanked with 450 μL of DSC buffer and 50 μL of DMSO. The protein (sample) and buffer (blank) were both heated from 10 to 90 °C with a scan rate of 60 °C/h and a filtering period of 10 s. The difference in heat required to raise the temperature of the sample as compared to the blank is measured as a function of temperature. The data was plotted using Origin 7.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">6.  Small Molecule Inhibitors</h3><div class="NLM_p last">PLX4032 (vemurafenib) was purchased from Santa Cruz Biotechnology (no. sc-364643). Sorafenib was purchased from Santa Cruz Biotechnology (no. sc-220125). TAK632 was purchased from BioVision Inc. (no. 2473-5).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">7.  General Chemistry Information</h3><div class="NLM_p last">Solvents used for extraction and purification were HPLC grade from Fisher. Unless otherwise indicated, all reactions were run under an inert atmosphere of argon. Anhydrous tetrahydrofuran, diethyl ether, and toluene were obtained via passage through an activated alumina column. Merck precoated silica gel plates (250 mm, 60 F254) were used for analytical TLC. Spots were visualized using 254 nm ultraviolet light, with either anisaldehyde or potassium permanganate stains as visualizing agents. Chromatographic purifications were performed on Sorbent Technologies silica gel (particle size 32–63 μm). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded at 500 and 125 MHz or 360 and 90 MHz, respectively, in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or CD<sub>3</sub>OD on a Bruker AM-500, a DRX-500, or a DMX-360 spectrometer. Chemical shifts are reported relative to internal chloroform (δ 7.26 for <sup>1</sup>H, δ 77.0 for <sup>13</sup>C), DMSO-<i>d</i><sub>6</sub> (δ 2.50 for <sup>1</sup>H, δ 39.5 for <sup>13</sup>C), or CD<sub>3</sub>OD (δ 3.31 for <sup>1</sup>H, δ 49.0 for <sup>13</sup>C). Infrared spectra were recorded on a NaCl plate using a PerkinElmer 1600 series Fourier transform spectrometer. High resolution mass spectra were obtained by Dr. Rakesh Kohli at the University of Pennsylvania Mass Spectrometry Service Center on an Autospec high resolution double-focusing electrospray ionization/chemical ionization spectrometer with either DEC 11/73 or OPUS software data system. All compounds were chromatographically homogeneous materials that were determined to be >95% pure by <sup>1</sup>H and <sup>13</sup>C NMR, and where necessary, HPLC.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">8.  Synthesis of TAK-X-TAK Dimers</h3><div class="NLM_p">To diacids <b>2</b>–<b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (0.225 mmol), TAK aminobenzothiazole <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (0.472 mmol), and DIPEA (1.3 mmol) in DMF (0.3 M) was added BEP (0.582 mmol). The reaction was then stirred at 25 °C for 18 h. The reaction was then quenched with brine and extracted with 9:1 ethyl acetate:THF. The combined organic fractions were then washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford a crude solid. The crude mixture was purified by silica gel column chromatography (MeOH/DCM) and then purified by preparative thin layer chromatography (MeOH/DCM) to afford TAK-X-TAK dimers as thin films.</div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> TAK-0-TAK</h4><div class="NLM_p last">Thin film; yield = 15%. <sup>1</sup>H NMR (500 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.35 (s, 1H), 8.17 (s, 2H), 7.99 (d, <i>J</i> = 9.0 Hz, 2H), 7.73 (s, 1H), 7.68 (d, <i>J</i> = 7.2 Hz, 2H), 7.63–7.52 (m, 3H), 7.31–7.24 (m, 2H), 7.14 (d, <i>J</i> = 8.9, 1.6 Hz, 2H), 6.93 (dd, <i>J</i> = 9.1, 3.7 Hz, 2H), 4.70 (s, 3H), 3.99 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 170.03, 169.74, 157.46, 156.34, 151.64, 151.21, 149.30, 149.28, 144.81, 142.46, 139.03, 137.30, 136.30, 133.87, 129.68, 129.64, 129.43, 129.19, 127.97, 127.87, 127.18, 126.28, 126.25, 126.22, 126.20, 125.68, 123.76, 123.73, 123.52, 117.20, 117.11, 116.94, 115.65, 115.59, 114.71, 114.13, 95.83, 70.02, 42.36 ppm. FT-IR (neat): 1703, 1663, 1625, 1595, 1545 cm<sup>–1</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>50</sub>H<sub>30</sub>F<sub>8</sub>N<sub>8</sub>O<sub>7</sub>S<sub>2</sub> (M + Na)<sup>+</sup> 1093.1449, found 1093.1472.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> TAK-2-TAK</h4><div class="NLM_p last">Thin film; yield = 6%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.21 (s, 1H), 7.93 (d, <i>J</i> = 9.0 Hz, 1H), 7.83 (s, 0H), 7.67 (s, 1H), 7.59 (s, 3H), 7.57–7.49 (m, 1H), 7.41–7.30 (m, 1H), 7.02 (d, <i>J</i> = 9.0 Hz, 1H), 6.94 (d, <i>J</i> = 8.9 Hz, 1H), 4.34 (s, 2H), 3.88 (s, 2H), 3.79–3.72 (m, 3H), 3.69–3.62 (m, 3H) ppm. <sup>13</sup>C NMR (126 MHz, DMSO) δ 170.35, 169.34, 157.14, 155.72, 151.26, 151.24, 150.80, 148.87, 144.42, 136.92, 135.88, 133.48, 129.61, 129.29, 129.26, 129.04, 128.79, 128.54, 127.57, 127.46, 126.60, 125.90, 125.87, 125.84, 125.81, 125.30, 123.40, 123.37, 123.34, 123.31, 123.14, 120.97, 116.70, 116.62, 116.52, 115.20, 115.14, 114.28, 113.75, 113.63, 95.31, 70.38, 69.85, 69.32, 41.97 ppm. FT-IR (neat): 1675, 1596, 1544, 1485, 1460 cm<sup>–1</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>54</sub>H<sub>38</sub>F<sub>8</sub>N<sub>8</sub>O<sub>9</sub>S<sub>2</sub> (M + Na)<sup>+</sup> 1181.1973, found 1181.1975</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> TAK-3-TAK</h4><div class="NLM_p last">Thin film; yield = 8%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.44 (s, 1H), 10.18 (s, 1H), 7.95 (dd, <i>J</i> = 9.1, 4.1 Hz, 1H), 7.83 (s, 1H), 7.66 (s, 1H), 7.63–7.49 (m, 3H), 7.38–7.30 (m, 1H), 7.04 (s, 1H), 6.98–6.90 (m, 1H), 4.32 (s, 2H), 3.86 (s, 2H), 3.72–3.65 (m, 2H), 3.60 (s, 4H) ppm. <sup>13</sup>C NMR (126 MHz, DMSO) δ 170.26, 169.38, 157.00, 155.83, 151.25, 150.80, 148.87, 144.43, 136.93, 135.87, 133.52, 129.33, 129.30, 129.26, 129.05, 128.80, 128.55, 127.60, 127.49, 126.75, 126.66, 125.92, 125.83, 125.33, 123.38, 123.16, 116.73, 116.66, 116.57, 115.24, 114.34, 113.80, 113.69, 95.35, 70.52, 69.75, 69.31, 41.98 ppm. FT-IR (neat): 1690, 1596, 1537, 1458, 1431 cm<sup>–1</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>56</sub>H<sub>42</sub>F<sub>8</sub>N<sub>8</sub>O<sub>10</sub>S<sub>2</sub> (M + H)<sup>+</sup> 1203.2416, found 1203.2382.</div></div><div id="sec4_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> TAK-4-TAK</h4><div class="NLM_p last">Thin film; yield = 10%. <sup>1</sup>H NMR (500 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.34 (s, 1H), 8.12 (dd, <i>J</i> = 6.6, 3.1 Hz, 1H), 7.86 (d, <i>J</i> = 9.0 Hz, 1H), 7.71 (s, 1H), 7.65 (d, <i>J</i> = 7.9 Hz, 1H), 7.60–7.48 (m, 2H), 7.23 (dd, <i>J</i> = 10.7, 9.0 Hz, 1H), 7.03 (d, <i>J</i> = 9.0 Hz, 1H), 6.90 (ddd, <i>J</i> = 9.0, 3.9, 3.1 Hz, 1H), 4.32 (s, 2H), 3.96 (s, 2H), 3.87–3.80 (m, 4H), 3.79–3.70 (m, 4H) ppm. <sup>13</sup>C NMR (126 MHz, acetone-<i>d</i><sub>6</sub>) δ 171.48, 170.01, 158.00, 157.26, 152.84, 152.82, 151.44, 149.52, 145.73, 137.75, 137.44, 134.37, 131.22, 130.97, 130.71, 130.46, 130.09, 129.09, 128.99, 127.38, 127.10, 127.06, 127.03, 127.00, 124.47, 124.45, 124.41, 124.38, 124.28, 117.50, 117.08, 116.90, 115.68, 115.62, 114.88, 114.02, 97.17, 72.52, 71.45, 71.11, 70.96, 70.54, 43.56 ppm. FT-IR (neat): 1684, 1625, 1592, 1538, 11487 cm<sup>–1</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>58</sub>H<sub>46</sub>F<sub>8</sub>N<sub>8</sub>O<sub>11</sub>S<sub>2</sub> (M + Na)<sup>+</sup> 1269.2497, found 1269.2457.</div></div><div id="sec4_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> TAK-6-TAK</h4><div class="NLM_p last">Thin film; yield = 7%. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 10.67 (s, 1H), 8.11 (dd, <i>J</i> = 6.6, 3.1 Hz, 1H), 7.78 (d, <i>J</i> = 9.0 Hz, 1H), 7.62–7.44 (m, 5H), 7.06 (t, <i>J</i> = 10.4, 8.9 Hz, 1H), 6.94 (d, <i>J</i> = 9.0 Hz, 1H), 6.80–6.74 (m, 1H), 4.30 (s, 2H), 3.84–3.69 (m, 11H), 3.66–3.57 (m, 5H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 169.48, 168.09, 159.11, 156.87, 156.62, 151.73, 149.96, 148.04, 144.53, 136.96, 134.64, 132.73, 131.33, 131.07, 129.41, 127.14, 127.05, 126.25, 126.09, 126.06, 124.85, 124.42, 124.40, 116.16, 115.71, 115.55, 115.09, 114.03, 112.80, 96.53, 71.56, 70.68, 70.43, 70.39, 70.36, 70.15, 69.90, 43.98 ppm. FT-IR (neat): 1693, 1595, 1537, 1485, 1456 cm<sup>–1</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>62</sub>H<sub>54</sub>F<sub>8</sub>N<sub>8</sub>O<sub>13</sub>S<sub>2</sub> (M + H)<sup>+</sup> 1335.3202, found 1335.3214.</div></div><div id="sec4_8_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> TAK-L</h4><div class="NLM_p">To a solution 2-(2-methoxyethoxy) acetic acid <b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a; 57 μL, 0.504 mmol), TAK benzotriazole <b>1</b><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a; 0.232 mg, 0.458 mmol), and DIPEA (0.498 mL, 2.8 mmol) in DMF (1.5 mL) was added BEP (0.169 g, 0.620 mmol). The reaction was then stirred at 25 °C for 24 h. The reaction was then quenched with brine and extracted with 9:1 ethyl acetate:THF. The combined organic fractions were then washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford a crude foam. The crude product was purified by silica gel column chromatography (5% MeOH/DCM) and then purified by preparative thin layer chromatography (4% MeOH/DCM) to afford TAK-L <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a) as a white foam.</div><div class="NLM_p last">Yield = 0.128 g (44%). <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 10.91 (s, 1H), 8.15 (dd, <i>J</i> = 6.4, 3.1 Hz, 1H), 7.84 (d, <i>J</i> = 9.0 Hz, 1H), 7.62–7.48 (m, 4H), 7.48–7.41 (m, 1H), 7.08 (t, <i>J</i> = 10.5, 8.9 Hz, 1H), 6.97 (d, <i>J</i> = 9.0 Hz, 1H), 6.79 (ddd, <i>J</i> = 8.9, 4.1, 2.9 Hz, 1H), 4.30 (s, 2H), 3.87–3.77 (m, 4H), 3.69–3.62 (m, 2H), 3.57 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 170.31, 168.88, 168.81, 156.95, 156.41, 151.84, 150.45, 148.53, 144.90, 136.73, 136.50, 133.28, 130.24, 129.99, 129.73, 129.48, 129.04, 128.15, 128.05, 127.96, 127.56, 126.52, 126.00, 125.96, 123.40, 123.36, 116.62, 116.02, 115.85, 114.59, 114.53, 113.83, 113.06, 96.25, 71.46, 71.18, 69.58, 57.95, 42.56 ppm. FT-IR (neat): 1686, 1533, 1486, 1458, 1429 cm<sup>–1</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>22</sub>N<sub>4</sub>O<sub>5</sub>F<sub>4</sub>S (M + Na)<sup>+</sup> 625.1145, found 625.144.</div></div><div id="sec4_8_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-(2-(2-(2-Oxo-2-(thiazol-2-ylamino)ethoxy)ethoxy)ethoxy)acetic Acid</h4><div class="NLM_p">To 3,6,9-trioxaundecandioic acid <b>3</b> (2.5 g, 11.25 mmol) in DCM (50 mL) was added DCC (2.32 g, 11.25 mmol). The reaction was then stirred at 25 °C for 18 h. The resulting suspension was then filtered and rinsed with chilled DCM. The filtrate was concentrated to afford the crude anhydride, which was taken directly on to the next step. The anhydride was dissolved with dry THF and was then treated with 2-aminothiazole (1.12 g, 11.25 mmol). The reaction was stirred for 3 h at 25 °C, and volatiles then removed by evaporation under reduced pressure. The resulting solid was then suspended in Et<sub>2</sub>O and filtered. The solid was then rinsed with chilled Et<sub>2</sub>O. The crude solid was then purified by silica gel column chromatography (2–10% MeOH/DCM) to give 2-(2-(2-(2-oxo-2-(thiazol-2-ylamino)ethoxy)ethoxy)ethoxy)acetic acid.</div><div class="NLM_p last">Pale-yellow solid; yield = 1.57 g (46% yield). <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.46 (d, <i>J</i> = 3.7 Hz, 1H), 7.14 (d, <i>J</i> = 3.7 Hz, 1H), 4.29 (s, 2H), 4.11 (d, <i>J</i> = 3.4 Hz, 2H), 3.81–3.71 (m, 8H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 171.68, 168.50, 157.37, 137.65, 113.68, 70.49, 69.81, 69.75, 69.60, 69.24, 67.59, 40.02, 39.86, 39.69, 39.52, 39.35, 39.19, 39.02. IR (neat): 3200, 1719, 1689, 1495, 1063 cm<sup>–1</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>48</sub>H<sub>41</sub>N<sub>6</sub>O<sub>8</sub>F<sub>4</sub>S<sub>2</sub> (M + H)<sup>+</sup> 305.0822, found 305.0807.</div></div><div id="sec4_8_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> TAK-L-C</h4><div class="NLM_p">To a solution of 2-(2-(2-(2-oxo-2-(thiazol-2-ylamino)ethoxy)ethoxy)ethoxy)acetic acid (0.159 mg, 0.524 mmol), TAK aminobenzothiazole<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (0.085 mg, 0.174 mmol), and TEA (0.243 mL, 1.74 mmol) in DMF (0.587 mL) was added T3P (0.333 mL, 0.524 mmol) in DMF (1:1; v/v) dropwise. The reaction was then stirred at 25 °C for 18 h. The reaction was then quenched with brine and extracted with 9:1 ethyl acetate: THF. The combined organic fractions were then washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford a crude solid. The crude product was then purified by preparative thin layer chromatography (3% MeOH/chloroform) to afford TAK-control-2 as a thin film.</div><div class="NLM_p last">Thin film; yield = 0.135g (55% yield). <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 10.55 (s, 1H), 10.35 (s, 1H), 8.11 (dd, <i>J</i> = 6.5, 3.1 Hz, 1H), 7.72 (d, <i>J</i> = 9.0 Hz, 1H), 7.62 (d, <i>J</i> = 3.4 Hz, 1H), 7.60–7.45 (m, 4H), 7.37 (d, <i>J</i> = 3.7 Hz, 1H), 7.06 (t, <i>J</i> = 9.7 Hz, 1H), 6.95–6.86 (m, 2H), 6.76 (dt, <i>J</i> = 8.9, 3.5 Hz, 1H), 4.31 (s, 2H), 4.24 (s, 2H), 4.06–3.99 (m, 4H), 3.85 (dt, <i>J</i> = 4.2, 2.3 Hz, 4H), 3.80 (s, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 169.38, 168.05, 157.07, 156.82, 156.63, 151.76, 149.96, 148.04, 144.29, 137.57, 137.38, 136.91, 136.46, 134.69, 132.74, 131.31, 131.05, 130.80, 129.39, 127.16, 127.07, 126.11, 126.09, 126.06, 126.03, 124.87, 124.41, 124.38, 122.71, 116.19, 115.68, 115.51, 115.09, 115.02, 114.03, 113.76, 112.88, 96.47, 71.41, 71.33, 70.42, 69.77, 69.74, 43.97 ppm. FT-IR (neat): 1692, 1595, 1533, 1484, 1455 cm<sup>–1</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>28</sub>N<sub>6</sub>O<sub>7</sub>F<sub>4</sub>S<sub>2</sub> (M + H)<sup>+</sup> 773.1475, found 773.1464.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00499" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This material is available free of charge via The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00499" class="ext-link">10.1021/acs.jmedchem.8b00499</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Information related to the sedimentation equilibrium raw data and residuals, as well as R509A mutation sedimentation velocity experiments and Vem-BisAmide-2 sedimentation velocity experiments (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00499/suppl_file/jm8b00499_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00499/suppl_file/jm8b00499_si_001.pdf">jm8b00499_si_001.pdf (515.99 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00499" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12555" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12555" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey D. Winkler</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8264-5491" title="Orcid link">http://orcid.org/0000-0001-8264-5491</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2156484f4a4d4453615240520f5451444f4f0f444554"><span class="__cf_email__" data-cfemail="62150b0c090e0710221103114c1712070c0c4c070617">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ronen Marmorstein</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics and the Abramson Family Cancer Research
Institute, Perelman School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4373-4752" title="Orcid link">http://orcid.org/0000-0003-4373-4752</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#98f5f9eaf5f7ead8ede8fdf6f6b6fdfced"><span class="__cf_email__" data-cfemail="5a373b283735281a2f2a3f3434743f3e2f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Grasso</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics and the Abramson Family Cancer Research
Institute, Perelman School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle A. Estrada</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kiara N. Berrios</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics and the Abramson Family Cancer Research
Institute, Perelman School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.G. and M.A.E. contributed equally to this work. M.G. and K.N.B. carried out biochemical and biophysical experiments under the direction of R.M. M.A.E. synthesized compounds under the direction of J.D.W. M.G. prepared Figures 1–7. M.G., M.A.E., J.D.W., and R.M. wrote the manuscript. All authors read and approved the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d175e1968-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24238" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24238" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by National Institutes of Health grant P01 CA114046 to R. Marmorstein, and J. D. Winkler, and a University of Pennsylvania Postdoctoral Fellowship for Academic Diversity to M. A. Estrada. We thank A. Olia and A. Vogt for helpful discussions regarding dimeric TAK binding possibilities. We acknowledge support of the DNA Sequencing Facility at the Perelman School of Medicine, University of Pennsylvania (NIH P30 CA016520).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">TBST</td><td class="NLM_def"><p class="first last">Tris-buffered saline with Tween-20</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">RTKs</td><td class="NLM_def"><p class="first last">receptor-tyrosine kinases</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">GST</td><td class="NLM_def"><p class="first last">glutathione S-transferase</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">analytical ultracentrifuge</p></td></tr><tr><td class="NLM_term">DSC</td><td class="NLM_def"><p class="first last">differential scanning calorimetry</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">SDS-PAGE</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate polyacrylamide gel electrophoresis</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">dithiothreitol</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">BEP</td><td class="NLM_def"><p class="first last">2-bromo-1-ethylpyridinium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">trimethylamine</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">propylphosphonic anhydride</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wellbrock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasarides, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">The RAF Proteins Take Centre Stage</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1038/nrm1498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnrm1498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=15520807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFemsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=875-885&author=C.+Wellbrockauthor=M.+Karasaridesauthor=R.+Marais&title=The+RAF+Proteins+Take+Centre+Stage&doi=10.1038%2Fnrm1498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF proteins take center stage</span></div><div class="casAuthors">Wellbrock, Claudia; Karasarides, Maria; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">875-885</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since their discovery over 20 years ago, the RAF proteins have been intensely studied.  For most of that time, the focus of the field has been the C-RAF isoform and its role as an effector of the RAS proteins.  However, a report that implicates B-RAF in human cancer has highlighted the importance of all members of this protein kinase family and recent studies have uncovered intriguing new data relating to their complex regulation and biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvN4GggcdfU7Vg90H21EOLACvtfcHk0li72__g67qSDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFemsLs%253D&md5=95f0a579b4c852fbe80a54befb88b052</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm1498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1498%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DKarasarides%26aufirst%3DM.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DThe%2520RAF%2520Proteins%2520Take%2520Centre%2520Stage%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D875%26epage%3D885%26doi%3D10.1038%2Fnrm1498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignell, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clegg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woffendin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmidou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mould, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayatilake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusterson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard-Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenevix-Trench, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seigler, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Mutations of the BRAF Gene in Human Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.1038/nature00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+Gene+in+Human+Cancer&doi=10.1038%2Fnature00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0li7YmDnWJNHpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520Gene%2520in%2520Human%2520Cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954%26doi%3D10.1038%2Fnature00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikenoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikiba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijichi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aragaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omata, M.</span></span> <span> </span><span class="NLM_article-title">Functional Analysis of Mutations Within the Kinase Activation Segment of B-Raf in Human Colorectal Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8132</span>– <span class="NLM_lpage">8137</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=8132-8137&author=T.+Ikenoueauthor=Y.+Hikibaauthor=F.+Kanaiauthor=Y.+Tanakaauthor=J.+Imamuraauthor=T.+Imamuraauthor=M.+Ohtaauthor=H.+Ijichiauthor=K.+Tateishiauthor=T.+Kawakamiauthor=J.+Aragakiauthor=M.+Matsumuraauthor=T.+Kawabeauthor=M.+Omata&title=Functional+Analysis+of+Mutations+Within+the+Kinase+Activation+Segment+of+B-Raf+in+Human+Colorectal+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIkenoue%26aufirst%3DT.%26aulast%3DHikiba%26aufirst%3DY.%26aulast%3DKanai%26aufirst%3DF.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DJ.%26aulast%3DImamura%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DIjichi%26aufirst%3DH.%26aulast%3DTateishi%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DT.%26aulast%3DAragaki%26aufirst%3DJ.%26aulast%3DMatsumura%26aufirst%3DM.%26aulast%3DKawabe%26aufirst%3DT.%26aulast%3DOmata%26aufirst%3DM.%26atitle%3DFunctional%2520Analysis%2520of%2520Mutations%2520Within%2520the%2520Kinase%2520Activation%2520Segment%2520of%2520B-Raf%2520in%2520Human%2520Colorectal%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D8132%26epage%3D8137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical Efficacy Of A RAF Inhibitor Needs A Broad Target Blockade In BRAF-Mutant Melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">596</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+Efficacy+Of+A+RAF+Inhibitor+Needs+A+Broad+Target+Blockade+In+BRAF-Mutant+Melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520Efficacy%2520Of%2520A%2520RAF%2520Inhibitor%2520Needs%2520A%2520Broad%2520Target%2520Blockade%2520In%2520BRAF-Mutant%2520Melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rheault, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjabeng, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossanese, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnone, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smitheman, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane-Carson, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of Dabrafenib: A Selective Inhibitor of RAF Kinases with Antitumor Activity Against B-RAF Driven Tumors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/ml4000063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=358-362&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithemanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G.+Mossauthor=D.+E.+Uehling&title=Discovery+of+Dabrafenib%3A+A+Selective+Inhibitor+of+RAF+Kinases+with+Antitumor+Activity+Against+B-RAF+Driven+Tumors&doi=10.1021%2Fml4000063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520Dabrafenib%253A%2520A%2520Selective%2520Inhibitor%2520of%2520RAF%2520Kinases%2520with%2520Antitumor%2520Activity%2520Against%2520B-RAF%2520Driven%2520Tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D358%26epage%3D362%26doi%3D10.1021%2Fml4000063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mutated, Activated BRAF in Metastatic Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&issue=9&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+Mutated%2C+Activated+BRAF+in+Metastatic+Melanoma&doi=10.1056%2FNEJMoa1002011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lhC-p--j2ss_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520Mutated%252C%2520Activated%2520BRAF%2520in%2520Metastatic%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D9%26spage%3D809%26epage%3D819%26doi%3D10.1056%2FNEJMoa1002011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nazarian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sazegar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">Melanomas Acquire Resistance to BRAF(V600E) Inhibition by RTK or N-RAS Upregulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span> (<span class="NLM_issue">7326</span>),  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1038/nature09626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature09626" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=973-977&issue=7326&author=R.+Nazarianauthor=H.+Shiauthor=Q.+Wangauthor=X.+Kongauthor=R.+C.+Koyaauthor=H.+Leeauthor=Z.+Chenauthor=M.+K.+Leeauthor=N.+Attarauthor=H.+Sazegarauthor=T.+Chodonauthor=S.+F.+Nelsonauthor=G.+McArthurauthor=J.+A.+Sosmanauthor=A.+Ribasauthor=R.+S.+Lo&title=Melanomas+Acquire+Resistance+to+BRAF%28V600E%29+Inhibition+by+RTK+or+N-RAS+Upregulation&doi=10.1038%2Fnature09626"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature09626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09626%26sid%3Dliteratum%253Aachs%26aulast%3DNazarian%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DM.%2BK.%26aulast%3DAttar%26aufirst%3DN.%26aulast%3DSazegar%26aufirst%3DH.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DMelanomas%2520Acquire%2520Resistance%2520to%2520BRAF%2528V600E%2529%2520Inhibition%2520by%2520RTK%2520or%2520N-RAS%2520Upregulation%26jtitle%3DNature%26date%3D2010%26volume%3D468%26issue%3D7326%26spage%3D973%26epage%3D977%26doi%3D10.1038%2Fnature09626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Prime Wild-Type RAF to Activate the MAPK Pathway and Enhance Growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&issue=7287&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+Inhibitors+Prime+Wild-Type+RAF+to+Activate+the+MAPK+Pathway+and+Enhance+Growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0li8fYwQjrlyXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520Inhibitors%2520Prime%2520Wild-Type%2520RAF%2520to%2520Activate%2520the%2520MAPK%2520Pathway%2520and%2520Enhance%2520Growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Transactivate RAF Dimers and ERK Signaling in Cells with Wild-Type BRAF</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nature08902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&issue=7287&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+Inhibitors+Transactivate+RAF+Dimers+and+ERK+Signaling+in+Cells+with+Wild-Type+BRAF&doi=10.1038%2Fnature08902"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520Inhibitors%2520Transactivate%2520RAF%2520Dimers%2520and%2520ERK%2520Signaling%2520in%2520Cells%2520with%2520Wild-Type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D427%26epage%3D430%26doi%3D10.1038%2Fnature08902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stites, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germino, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meharena, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stork, P. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornev, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span> <span> </span><span class="NLM_article-title">Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1036</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2013.07.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.cell.2013.07.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=23993095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGru77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2013&pages=1036-1046&author=J.+Huauthor=E.+C.+Stitesauthor=H.+Yuauthor=E.+A.+Germinoauthor=H.+S.+Meharenaauthor=P.+J.+S.+Storkauthor=A.+P.+Kornevauthor=S.+S.+Taylorauthor=A.+S.+Shaw&title=Allosteric+Activation+of+Functionally+Asymmetric+RAF+Kinase+Dimers&doi=10.1016%2Fj.cell.2013.07.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers</span></div><div class="casAuthors">Hu, Jiancheng; Stites, Edward C.; Yu, Haiyang; Germino, Elizabeth A.; Meharena, Hiruy S.; Stork, Philip J. S.; Kornev, Alexandr P.; Taylor, Susan S.; Shaw, Andrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1036-1046</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although RAF kinases are crit. for controlling cell growth, their mechanism of activation is incompletely understood.  Recently, dimerization was shown to be important for activation.  Here we show that the dimer is functionally asym. with one kinase functioning as an activator to stimulate activity of the partner, receiver kinase.  The activator kinase did not require kinase activity but did require N-terminal phosphorylation that functioned allosterically to induce cis-autophosphorylation of the receiver kinase.  Based on modeling of the hydrophobic spine assembly, we also engineered a constitutively active mutant that was independent of Ras, dimerization, and activation-loop phosphorylation.  As N-terminal phosphorylation of BRAF is constitutive, BRAF initially functions to activate CRAF.  N-terminal phosphorylation of CRAF was dependent on MEK, suggesting a feedback mechanism and explaining a key difference between BRAF and CRAF.  Our work illuminates distinct steps in RAF activation that function to assemble the active conformation of the RAF kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU3Cusz6x-4bVg90H21EOLACvtfcHk0li8fYwQjrlyXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGru77N&md5=e8f5cfdfeb1c9f974b719e8c9716b687</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.07.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.07.046%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DStites%26aufirst%3DE.%2BC.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DGermino%26aufirst%3DE.%2BA.%26aulast%3DMeharena%26aufirst%3DH.%2BS.%26aulast%3DStork%26aufirst%3DP.%2BJ.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26atitle%3DAllosteric%2520Activation%2520of%2520Functionally%2520Asymmetric%2520RAF%2520Kinase%2520Dimers%26jtitle%3DCell%26date%3D2013%26volume%3D154%26spage%3D1036%26epage%3D1046%26doi%3D10.1016%2Fj.cell.2013.07.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajakulendran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefrançois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">A Dimerization-Dependent Mechanism Drives RAF Catalytic Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>461</i></span> (<span class="NLM_issue">7263</span>),  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1038/nature08314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature08314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=19727074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOmu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2009&pages=542-545&issue=7263&author=T.+Rajakulendranauthor=M.+Sahmiauthor=M.+Lefran%C3%A7oisauthor=F.+Sicheriauthor=M.+Therrien&title=A+Dimerization-Dependent+Mechanism+Drives+RAF+Catalytic+Activation&doi=10.1038%2Fnature08314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A dimerization-dependent mechanism drives RAF catalytic activation</span></div><div class="casAuthors">Rajakulendran, Thanashan; Sahmi, Malha; Lefrancois, Martin; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">7263</span>),
    <span class="NLM_cas:pages">542-545</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ERK (extracellular signal-regulated kinase) pathway is an evolutionarily conserved signal transduction module that controls cellular growth, differentiation and survival.  Activation of receptor tyrosine kinases (RTKs) by the binding of growth factors initiates GTP loading of RAS, which triggers the initial steps in the activation of the ERK pathway by modulating RAF family kinase function.  Once activated, RAF participates in a sequential cascade of phosphorylation events that activate MEK, and in turn ERK.  Unbridled signalling through the ERK pathway caused by activating mutations in RTKs, RAS or RAF has been linked to several human cancers.  Of note, one member of the RAF family, BRAF, is the most frequently mutated oncogene in the kinase superfamily.  Not surprisingly, there has been a colossal effort to understand the underlying regulation of this family of kinases.  In particular, the process by which the RAF kinase domain becomes activated towards its substrate MEK remains of topical interest.  Here, using Drosophila Schneider S2 cells, we demonstrate that RAF catalytic function is regulated in response to a specific mode of dimerization of its kinase domain, which we term the side-to-side dimer.  Moreover, we find that the RAF-related pseudo-kinase KSR (kinase suppressor of Ras) also participates in forming side-to-side heterodimers with RAF and can thereby trigger RAF activation.  This mechanism provides an elegant explanation for the longstanding conundrum about RAF catalytic activation and also provides an explanation for the capacity of KSR, despite lacking catalytic function, to directly mediate RAF activation.  We also show that RAF side-to-side dimer formation is essential for aberrant signalling by oncogenic BRAF mutants, and identify an oncogenic mutation that acts specifically by promoting side-to-side dimerization.  Together, our data identify the side-to-side dimer interface of RAF as a potential therapeutic target for intervention in BRAF-dependent tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbnxNSbvudjbVg90H21EOLACvtfcHk0lgshQ0T3S_Hgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOmu7fI&md5=2248d71ce37a2bac4e508a1097e95cba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature08314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08314%26sid%3Dliteratum%253Aachs%26aulast%3DRajakulendran%26aufirst%3DT.%26aulast%3DSahmi%26aufirst%3DM.%26aulast%3DLefran%25C3%25A7ois%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DA%2520Dimerization-Dependent%2520Mechanism%2520Drives%2520RAF%2520Catalytic%2520Activation%26jtitle%3DNature%26date%3D2009%26volume%3D461%26issue%3D7263%26spage%3D542%26epage%3D545%26doi%3D10.1038%2Fnature08314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidorn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression Through CRAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=S.+J.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-Dead+BRAF+and+Oncogenic+RAS+Cooperate+to+Drive+Tumor+Progression+Through+CRAF&doi=10.1016%2Fj.cell.2009.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0lgshQ0T3S_Hgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DS.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-Dead%2520BRAF%2520and%2520Oncogenic%2520RAS%2520Cooperate%2520to%2520Drive%2520Tumor%2520Progression%2520Through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.cell.2009.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janakiraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misteli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitor Resistance is Mediated by Dimerization of Aberrantly Spliced BRAF(V600E)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>480</i></span> (<span class="NLM_issue">7377</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1038/nature10662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature10662" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=387-390&issue=7377&author=P.+I.+Poulikakosauthor=Y.+Persaudauthor=M.+Janakiramanauthor=X.+Kongauthor=C.+Ngauthor=G.+Moriceauauthor=H.+Shiauthor=M.+Atefiauthor=B.+Titzauthor=M.+T.+Gabayauthor=M.+Saltonauthor=K.+B.+Dahlmanauthor=M.+Tadiauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=M.+C.+Kelleyauthor=T.+Misteliauthor=P.+B.+Chapmanauthor=J.+A.+Sosmanauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=N.+Rosenauthor=D.+B.+Solit&title=RAF+Inhibitor+Resistance+is+Mediated+by+Dimerization+of+Aberrantly+Spliced+BRAF%28V600E%29&doi=10.1038%2Fnature10662"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10662%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DJanakiraman%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DTitz%26aufirst%3DB.%26aulast%3DGabay%26aufirst%3DM.%2BT.%26aulast%3DSalton%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DRAF%2520Inhibitor%2520Resistance%2520is%2520Mediated%2520by%2520Dimerization%2520of%2520Aberrantly%2520Spliced%2520BRAF%2528V600E%2529%26jtitle%3DNature%26date%3D2011%26volume%3D480%26issue%3D7377%26spage%3D387%26epage%3D390%26doi%3D10.1038%2Fnature10662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nespi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanftner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors that Evade Paradoxical MAPK Pathway Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>526</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1038/nature14982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature14982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=26466569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWitLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=583-586&author=C.+Zhangauthor=W.+Spevakauthor=Y.+Zhangauthor=E.+A.+Burtonauthor=Y.+Maauthor=G.+Habetsauthor=J.+Zhangauthor=J.+Linauthor=T.+Ewingauthor=B.+Matusowauthor=G.+Tsangauthor=A.+Marimuthuauthor=H.+Choauthor=G.+Wuauthor=W.+Wangauthor=D.+Fongauthor=H.+Nguyenauthor=S.+Shiauthor=P.+Womackauthor=M.+Nespiauthor=R.+Shellooeauthor=H.+Cariasauthor=B.+Powellauthor=E.+Lightauthor=L.+Sanftnerauthor=J.+Waltersauthor=J.+Tsaiauthor=B.+L.+Westauthor=G.+Visorauthor=H.+Rezaeiauthor=P.+S.+Linauthor=K.+Nolopauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=G.+Bollag&title=RAF+Inhibitors+that+Evade+Paradoxical+MAPK+Pathway+Activation&doi=10.1038%2Fnature14982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors that evade paradoxical MAPK pathway activation</span></div><div class="casAuthors">Zhang, Chao; Spevak, Wayne; Zhang, Ying; Burton, Elizabeth A.; Ma, Yan; Habets, Gaston; Zhang, Jiazhong; Lin, Jack; Ewing, Todd; Matusow, Bernice; Tsang, Garson; Marimuthu, Adhirai; Cho, Hanna; Wu, Guoxian; Wang, Weiru; Fong, Daniel; Nguyen, Hoa; Shi, Songyuan; Womack, Patrick; Nespi, Marika; Shellooe, Rafe; Carias, Heidi; Powell, Ben; Light, Emily; Sanftner, Laura; Walters, Jason; Tsai, James; West, Brian L.; Visor, Gary; Rezaei, Hamid; Lin, Paul S.; Nolop, Keith; Ibrahim, Prabha N.; Hirth, Peter; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7574</span>),
    <span class="NLM_cas:pages">583-586</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Oncogenic activation of BRAF fuels cancer growth by constitutively promoting RAS-independent mitogen-activated protein kinase (MAPK) pathway signalling.  Accordingly, RAF inhibitors have brought substantially improved personalized treatment of metastatic melanoma.  However, these targeted agents have also revealed an unexpected consequence: stimulated growth of certain cancers.  Structurally diverse ATP-competitive RAF inhibitors can either inhibit or paradoxically activate the MAPK pathway, depending whether activation is by BRAF mutation or by an upstream event, such as RAS mutation or receptor tyrosine kinase activation.  Here we have identified next-generation RAF inhibitors (dubbed 'paradox breakers') that suppress mutant BRAF cells without activating the MAPK pathway in cells bearing upstream activation.  In cells that express the same HRAS mutation prevalent in squamous tumors from patients treated with RAF inhibitors, the first-generation RAF inhibitor vemurafenib stimulated in vitro and in vivo growth and induced expression of MAPK pathway response genes; by contrast the paradox breakers PLX7904 and PLX8394 had no effect.  Paradox breakers also overcame several known mechanisms of resistance to first-generation RAF inhibitors.  Dissocg. MAPK pathway inhibition from paradoxical activation might yield both improved safety and more durable efficacy than first-generation RAF inhibitors, a concept currently undergoing human clin. evaluation with PLX8394.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv_s6rL_GkBbVg90H21EOLACvtfcHk0ljHBNWqrrxtxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWitLfN&md5=e5e4c5e11a6c54d442a4ed7a2f21d76a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature14982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14982%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DEwing%26aufirst%3DT.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWomack%26aufirst%3DP.%26aulast%3DNespi%26aufirst%3DM.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLight%26aufirst%3DE.%26aulast%3DSanftner%26aufirst%3DL.%26aulast%3DWalters%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DVisor%26aufirst%3DG.%26aulast%3DRezaei%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DRAF%2520Inhibitors%2520that%2520Evade%2520Paradoxical%2520MAPK%2520Pathway%2520Activation%26jtitle%3DNature%26date%3D2015%26volume%3D526%26spage%3D583%26epage%3D586%26doi%3D10.1038%2Fnature14982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Effects of RAF Dimerization and its Inhibition on Normal and Disease-Associated RAF Signaling</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2012.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.molcel.2012.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=23352452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=751-758&author=A.+K.+Freemanauthor=D.+A.+Rittauthor=D.+K.+Morrison&title=Effects+of+RAF+Dimerization+and+its+Inhibition+on+Normal+and+Disease-Associated+RAF+Signaling&doi=10.1016%2Fj.molcel.2012.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling</span></div><div class="casAuthors">Freeman, Alyson K.; Ritt, Daniel A.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">751-758</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Raf kinases are essential for normal Ras-Raf-MEK-ERK pathway signaling, and activating mutations in components of this pathway are assocd. with a variety of human cancers, as well as the related developmental disorders Noonan, LEOPARD, and cardiofaciocutaneous syndromes.  Although the Raf kinases are known to dimerize during normal and disease-assocd. Raf signaling, the functional significance of Raf dimerization has not been fully elucidated.  Here, using mutational anal. and a peptide inhibitor, we show that dimerization is required for normal Ras-dependent Raf activation and for the biol. function of disease-assocd. Raf mutants with moderate, low, or impaired kinase activity.  However, dimerization is not needed for the function of B-Raf mutants with high catalytic activity, such as V600E-B-Raf.  Importantly, we find that a dimer interface peptide can effectively block Raf dimerization and inhibit Raf signaling when dimerization is required for Raf function, thus identifying the Raf dimer interface as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_CXtQf2fRqbVg90H21EOLACvtfcHk0ljHAph6Sz6Ujg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCqtr8%253D&md5=7c8dfaa1a8c01cd4d87cbd8ef364df8d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DA.%2BK.%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DEffects%2520of%2520RAF%2520Dimerization%2520and%2520its%2520Inhibition%2520on%2520Normal%2520and%2520Disease-Associated%2520RAF%2520Signaling%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D49%26spage%3D751%26epage%3D758%26doi%3D10.1016%2Fj.molcel.2012.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critton, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of a BRAF Kinase Domain Monomer Explains Basis for Allosteric Regulation</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnsmb.2924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=25437913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCksr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=37-44&issue=1&author=N.+Thevakumaranauthor=H.+Lavoieauthor=D.+A.+Crittonauthor=A.+Tebbenauthor=A.+Marinierauthor=F.+Sicheriauthor=M.+Therrien&title=Crystal+Structure+of+a+BRAF+Kinase+Domain+Monomer+Explains+Basis+for+Allosteric+Regulation&doi=10.1038%2Fnsmb.2924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation</span></div><div class="casAuthors">Thevakumaran, Neroshan; Lavoie, Hugo; Critton, David A.; Tebben, Andrew; Marinier, Anne; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reported RAF kinase domain structures adopt a side-to-side dimer configuration reflective of an 'on' state that underpins an allosteric mechanism of regulation.  Atomic details of the monomer 'off' state have been elusive.  Reinspection of the BRAF kinase domain structures revealed that sulfonamide inhibitors induce features of an off state, primarily a laterally displaced helix αC stabilized by the activation segment helix 1 (AS-H1).  These features correlated with the ability of sulfonamides to disrupt human BRAF homodimers in cells, in vitro and in crystals yielding a structure of BRAF in a monomer state.  The crystal structure revealed exaggerated, nonproductive positions of helix αC and AS-H1, the latter of which is the target of potent BRAF oncogenic mutations.  Together, this work provides formal proof of an allosteric link between the RAF dimer interface, the activation segment and the catalytic infrastructure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2mmFDDNHIrLVg90H21EOLACvtfcHk0ljHAph6Sz6Ujg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCksr7I&md5=0417ca047f52f6a425a3925fec6b5e05</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2924%26sid%3Dliteratum%253Aachs%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DCritton%26aufirst%3DD.%2BA.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DCrystal%2520Structure%2520of%2520a%2520BRAF%2520Kinase%2520Domain%2520Monomer%2520Explains%2520Basis%2520for%2520Allosteric%2520Regulation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26issue%3D1%26spage%3D37%26epage%3D44%26doi%3D10.1038%2Fnsmb.2924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavory, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padeganeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors that Stabilize a Closed RAF Kinase Domain Conformation Induce Dimerization</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnchembio.1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=23685672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=428-436&issue=7&author=H.+Lavoieauthor=N.+Thevakumaranauthor=G.+Gavoryauthor=J.+J.+Liauthor=A.+Padeganehauthor=S.+Guiralauthor=J.+Duchaineauthor=D.+Y.+Maoauthor=M.+Bouvierauthor=F.+Sicheriauthor=M.+Therrien&title=Inhibitors+that+Stabilize+a+Closed+RAF+Kinase+Domain+Conformation+Induce+Dimerization&doi=10.1038%2Fnchembio.1257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span></div><div class="casAuthors">Lavoie, Hugo; Thevakumaran, Neroshan; Gavory, Gwenaelle; Li, John J.; Padeganeh, Abbas; Guiral, Sebastien; Duchaine, Jean; Mao, Daniel Y. L.; Bouvier, Michel; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF kinases have a prominent role in cancer.  Their mode of activation is complex but critically requires dimerization of their kinase domains.  Unexpectedly, several ATP-competitive RAF inhibitors were recently found to promote dimerization and transactivation of RAF kinases in a RAS-dependent manner and, as a result, undesirably stimulate RAS/ERK pathway-mediated cell growth.  The mechanism by which these inhibitors induce RAF kinase domain dimerization remains unclear.  Here we describe bioluminescence resonance energy transfer-based biosensors for the extended RAF family that enable the detection of RAF dimerization in living cells.  Notably, we demonstrate the utility of these tools for profiling kinase inhibitors that selectively modulate RAF dimerization and for probing structural determinants of RAF dimerization in vivo.  Our findings, which seem generalizable to other kinase families allosterically regulated by kinase domain dimerization, suggest a model whereby ATP-competitive inhibitors mediate RAF dimerization by stabilizing a rigid closed conformation of the kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEtTJvsZ1FrVg90H21EOLACvtfcHk0ljHAph6Sz6Ujg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D&md5=f866ae6da93c5e2d7fec53b8dc0e6f2a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1257%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DGavory%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DPadeganeh%26aufirst%3DA.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DD.%2BY.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DInhibitors%2520that%2520Stabilize%2520a%2520Closed%2520RAF%2520Kinase%2520Domain%2520Conformation%2520Induce%2520Dimerization%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D7%26spage%3D428%26epage%3D436%26doi%3D10.1038%2Fnchembio.1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krepler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lujambio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity Against Oncogenic BRAF Signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.ccell.2016.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=27523909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=485-498&author=Z.+Karouliaauthor=Y.+Wuauthor=T.+A.+Ahmedauthor=Q.+Xinauthor=J.+Bollardauthor=C.+Kreplerauthor=X.+Wuauthor=C.+Zhangauthor=G.+Bollagauthor=M.+Herlynauthor=J.+A.+Faginauthor=A.+Lujambioauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=An+Integrated+Model+of+RAF+Inhibitor+Action+Predicts+Inhibitor+Activity+Against+Oncogenic+BRAF+Signaling&doi=10.1016%2Fj.ccell.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling</span></div><div class="casAuthors">Karoulia, Zoi; Wu, Yang; Ahmed, Tamer A.; Xin, Qisheng; Bollard, Julien; Krepler, Clemens; Wu, Xuewei; Zhang, Chao; Bollag, Gideon; Herlyn, Meenhard; Fagin, James A.; Lujambio, Amaia; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-498</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The complex biochem. effects of RAF inhibitors account for both the effectiveness and mechanisms of resistance to these drugs, but a unified mechanistic model has been lacking.  Here we show that RAF inhibitors exert their effects via two distinct allosteric mechanisms.  Drug resistance due to dimerization is detd. by the position of the αC helix stabilized by inhibitor, whereas inhibitor-induced RAF priming and dimerization are the result of inhibitor-induced formation of the RAF/RAS-GTP complex.  The biochem. effect of RAF inhibitor in cells is the combined outcome of the two mechanisms.  Therapeutic strategies including αC-helix-IN inhibitors are more effective in multiple mutant BRAF-driven tumor models, including colorectal and thyroid BRAFV600E cancers, in which first-generation RAF inhibitors have been ineffective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9VLWvQ7ojJrVg90H21EOLACvtfcHk0lh64fuvL3Z7OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I&md5=197711577048b889ea1dac8c87049a01</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DBollard%26aufirst%3DJ.%26aulast%3DKrepler%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DLujambio%26aufirst%3DA.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DAn%2520Integrated%2520Model%2520of%2520RAF%2520Inhibitor%2520Action%2520Predicts%2520Inhibitor%2520Activity%2520Against%2520Oncogenic%2520BRAF%2520Signaling%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D485%26epage%3D498%26doi%3D10.1016%2Fj.ccell.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventocilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksimoska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span> <span> </span><span class="NLM_article-title">Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF<sup>V600E</sup> Conformation</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2876</span>– <span class="NLM_lpage">2888</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2876-2888&issue=10&author=M.+Grassoauthor=M.+A.+Estradaauthor=C.+Ventocillaauthor=M.+Samantaauthor=J.+Maksimoskaauthor=J.+Villanuevaauthor=J.+D.+Winklerauthor=R.+Marmorstein&title=Chemically+Linked+Vemurafenib+Inhibitors+Promote+an+Inactive+BRAFV600E+Conformation&doi=10.1021%2Facschembio.6b00529"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00529%26sid%3Dliteratum%253Aachs%26aulast%3DGrasso%26aufirst%3DM.%26aulast%3DEstrada%26aufirst%3DM.%2BA.%26aulast%3DVentocilla%26aufirst%3DC.%26aulast%3DSamanta%26aufirst%3DM.%26aulast%3DMaksimoska%26aufirst%3DJ.%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DMarmorstein%26aufirst%3DR.%26atitle%3DChemically%2520Linked%2520Vemurafenib%2520Inhibitors%2520Promote%2520an%2520Inactive%2520BRAFV600E%2520Conformation%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3D2876%26epage%3D2888%26doi%3D10.1021%2Facschembio.6b00529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basile, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartsough, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplin, A. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mutant BRAF Splice Variant Signaling By Next-Generation, Selective RAF Inhibitors</span>. <i>Pigm. Cell Melanoma Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1111/pcmr.12218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1111%2Fpcmr.12218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=24422853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2nsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=479-484&author=K.+J.+Basileauthor=K.+Leauthor=E.+J.+Hartsoughauthor=A.+E.+Aplin&title=Inhibition+of+Mutant+BRAF+Splice+Variant+Signaling+By+Next-Generation%2C+Selective+RAF+Inhibitors&doi=10.1111%2Fpcmr.12218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors</span></div><div class="casAuthors">Basile, Kevin J.; Le, Kaitlyn; Hartsough, Edward J.; Aplin, Andrew E.</div><div class="citationInfo"><span class="NLM_cas:title">Pigment Cell & Melanoma Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-484</span>CODEN:
                <span class="NLM_cas:coden">PCMRCM</span>;
        ISSN:<span class="NLM_cas:issn">1755-1471</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Vemurafenib and dabrafenib block MEK-ERK1/2 signaling and cause tumor regression in the majority of advanced-stage BRAFV600E melanoma patients; however, acquired resistance and paradoxical signaling have driven efforts for more potent and selective RAF inhibitors.  Next-generation RAF inhibitors, such as PLX7904 (PB04), effectively inhibit RAF signaling in BRAFV600E melanoma cells without paradoxical effects in wild-type cells.  Furthermore, PLX7904 blocks the growth of vemurafenib-resistant BRAFV600E cells that express mutant NRAS.  Acquired resistance to vemurafenib and dabrafenib is also frequently driven by expression of mutation BRAF splice variants; thus, we tested the effects of PLX7904 and its clin. analog, PLX8394 (PB03), in BRAFV600E splice variant-mediated vemurafenib-resistant cells.  We show that paradox-breaker RAF inhibitors potently block MEK-ERK1/2 signaling, G1/S cell cycle events, survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAFV600E splice variants.  These data support the further investigation of paradox-breaker RAF inhibitors as a second-line treatment option for patients failing on vemurafenib or dabrafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovvoDjV1fbw7Vg90H21EOLACvtfcHk0liiD_-umb7DZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2nsbs%253D&md5=e9d363cc4fff1821674569c31b8980ee</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fpcmr.12218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcmr.12218%26sid%3Dliteratum%253Aachs%26aulast%3DBasile%26aufirst%3DK.%2BJ.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DHartsough%26aufirst%3DE.%2BJ.%26aulast%3DAplin%26aufirst%3DA.%2BE.%26atitle%3DInhibition%2520of%2520Mutant%2520BRAF%2520Splice%2520Variant%2520Signaling%2520By%2520Next-Generation%252C%2520Selective%2520RAF%2520Inhibitors%26jtitle%3DPigm.%2520Cell%2520Melanoma%2520Res.%26date%3D2014%26volume%3D27%26spage%3D479%26epage%3D484%26doi%3D10.1111%2Fpcmr.12218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tutuka, C. S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariadason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behren, A.</span></span> <span> </span><span class="NLM_article-title">PLX8394, A New Generation BRAF Inhibitor, Selectively Inhibits BRAF in Colonic Adenocarcinoa Cells and Prevents Paradoxical MAPK Pathway Activation</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">112</span>, <span class="refDoi"> DOI: 10.1186/s12943-017-0684-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1186%2Fs12943-017-0684-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=28659148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A280%3ADC%252BC1cjislamsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=112&author=C.+S.+A.+Tutukaauthor=M.+C.+Andrewsauthor=J.+M.+Mariadasonauthor=P.+Ioannidisauthor=C.+Hudsonauthor=J.+Cebonauthor=A.+Behren&title=PLX8394%2C+A+New+Generation+BRAF+Inhibitor%2C+Selectively+Inhibits+BRAF+in+Colonic+Adenocarcinoa+Cells+and+Prevents+Paradoxical+MAPK+Pathway+Activation&doi=10.1186%2Fs12943-017-0684-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation</span></div><div class="casAuthors">Tutuka Candani S A; Andrews Miles C; Mariadason John M; Ioannidis Paul; Hudson Christopher; Cebon Jonathan; Behren Andreas; Andrews Miles C; Cebon Jonathan; Andrews Miles C; Mariadason John M; Cebon Jonathan; Behren Andreas; Cebon Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BRAF inhibitors (BRAFi) are standard of care for the treatment of BRAF V600 mutation-driven metastatic melanoma, but can lead to paradoxical activation of the mitogen-activated protein kinase (MAPK) signalling pathway.  This can result in the promotion of precancerous lesions and secondary neoplasms, mainly (but not exclusively) associated with pre-existing mutations in RAS genes.  We previously reported a patient with synchronous BRAF-mutated metastatic melanoma and BRAF (wt) /KRAS (G12D)-metastatic colorectal cancer (CRC), whose CRC relapsed and progressed when treated with the BRAF inhibitor dabrafenib (GSK2118436).  We used tissue from the resected CRC metastasis to derive a cell line, LM-COL-1, which directly and reliably mimicked the clinical scenario including paradoxical activation of the MAPK signalling pathway resulting in increased cell proliferation upon dabrafenib treatment.  Novel BRAF inhibitors (PLX8394 and PLX7904), dubbed as "paradox breakers", were developed to inhibit V600 mutated oncogenic BRAF without causing paradoxical MAPK pathway activation.  In this study we used our LM-COL-1 model alongside multiple other CRC cell lines with varying mutational backgrounds to demonstrate and confirm that the paradox breaker PLX8394 retains on-target inhibition of mutated BRAF V600 without paradoxically promoting MAPK signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROdjRUxyfsDzDnmmyUf5qOfW6udTcc2eYh_M0kB1V_TLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjislamsw%253D%253D&md5=05424c425e63d4e55e491a1e4c52edfb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs12943-017-0684-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-017-0684-x%26sid%3Dliteratum%253Aachs%26aulast%3DTutuka%26aufirst%3DC.%2BS.%2BA.%26aulast%3DAndrews%26aufirst%3DM.%2BC.%26aulast%3DMariadason%26aufirst%3DJ.%2BM.%26aulast%3DIoannidis%26aufirst%3DP.%26aulast%3DHudson%26aufirst%3DC.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DBehren%26aufirst%3DA.%26atitle%3DPLX8394%252C%2520A%2520New%2520Generation%2520BRAF%2520Inhibitor%252C%2520Selectively%2520Inhibits%2520BRAF%2520in%2520Colonic%2520Adenocarcinoa%2520Cells%2520and%2520Prevents%2520Paradoxical%2520MAPK%2520Pathway%2520Activation%26jtitle%3DMol.%2520Cancer%26date%3D2017%26volume%3D16%26spage%3D112%26doi%3D10.1186%2Fs12943-017-0684-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okaniwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsutsumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tottori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">6478</span>– <span class="NLM_lpage">6494</span>, <span class="refDoi"> DOI: 10.1021/jm400778d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400778d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6478-6494&author=M.+Okaniwaauthor=M.+Hiroseauthor=T.+Aritaauthor=M.+Yabukiauthor=A.+Nakamuraauthor=T.+Takagiauthor=T.+Kawamotoauthor=N.+Uchiyamaauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=T.+Tottoriauthor=Y.+Inuiauthor=B.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Discovery+of+a+Selective+Kinase+Inhibitor+%28TAK-632%29+Targeting+Pan-RAF+Inhibition%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+C-7-Substituted+1%2C3-Benzothiazole+Derivatives&doi=10.1021%2Fjm400778d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives</span></div><div class="casAuthors">Okaniwa, Masanori; Hirose, Masaaki; Arita, Takeo; Yabuki, Masato; Nakamura, Akito; Takagi, Terufumi; Kawamoto, Tomohiro; Uchiyama, Noriko; Sumita, Akihiko; Tsutsumi, Shunichirou; Tottori, Tsuneaki; Inui, Yoshitaka; Sang, Bi-Ching; Yano, Jason; Aertgeerts, Kathleen; Yoshida, Sei; Ishikawa, Tomoyasu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6478-6494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivs. based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 inhibitor and developed a regioselective cyclization methodol. for the C-7-substituted 1,3-benzothiazole scaffold utilizing meta-substituted anilines.  Eventually, we selected 7-cyano deriv. I (TAK-632) as a development candidate and confirmed its binding mode by cocrystal structure with BRAF.  Accommodation of the 7-cyano group into the BRAF-selectivity pocket and the 3-(trifluoromethyl)phenyl acetamide moiety into the hydrophobic back pocket of BRAF in the DFG-out conformation contributed to enhanced RAF potency and selectivity vs VEGFR2.  Reflecting its potent pan-RAF inhibition and slow off-rate profile, I demonstrated significant cellular activity against mutated BRAF or mutated NRAS cancer cell lines.  Furthermore, in both A375 (BRAFV600E) and HMVII (NRASQ61K) xenograft models in rats, I demonstrated regressive antitumor efficacy by twice daily, 14-day repetitive administration without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2jcxKx47lWLVg90H21EOLACvtfcHk0liiD_-umb7DZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qsrzL&md5=60ccb75bcf7d7772cdf21468e26c141f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm400778d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400778d%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DTottori%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DY.%26aulast%3DSang%26aufirst%3DB.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520Kinase%2520Inhibitor%2520%2528TAK-632%2529%2520Targeting%2520Pan-RAF%2520Inhibition%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520C-7-Substituted%25201%252C3-Benzothiazole%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6478%26epage%3D6494%26doi%3D10.1021%2Fjm400778d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donelan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouitar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carideo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okaniwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7043</span>– <span class="NLM_lpage">7055</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1158%2F0008-5472.CAN-13-1825" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=7043-7055&issue=23&author=A.+Nakamuraauthor=T.+Aritaauthor=S.+Tsuchiyaauthor=J.+Donelanauthor=J.+Chouitarauthor=E.+Carideoauthor=K.+Galvinauthor=M.+Okaniwaauthor=T.+Ishikawaauthor=S.+Yoshida&title=Antitumor+Activity+of+the+Selective+Pan-RAF+Inhibitor+TAK-632+in+BRAF+Inhibitor-Resistant+Melanoma&doi=10.1158%2F0008-5472.CAN-13-1825"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1825%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DDonelan%26aufirst%3DJ.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DCarideo%26aufirst%3DE.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DS.%26atitle%3DAntitumor%2520Activity%2520of%2520the%2520Selective%2520Pan-RAF%2520Inhibitor%2520TAK-632%2520in%2520BRAF%2520Inhibitor-Resistant%2520Melanoma%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D23%26spage%3D7043%26epage%3D7055%26doi%3D10.1158%2F0008-5472.CAN-13-1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risom, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturgis, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegtli, W. C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine Inhibitors of B-RAF(V600E). Part 4: Rational Design and Kinase Selectivity Profile of Cell Potent Type II Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6237</span>– <span class="NLM_lpage">6241</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.bmcl.2012.08.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6237-6241&author=S.+Wenglowskyauthor=D.+Morenoauthor=E.+R.+Lairdauthor=S.+L.+Gloorauthor=L.+Renauthor=T.+Risomauthor=J.+Rudolphauthor=H.+L.+Sturgisauthor=W.+C.+Voegtli&title=Pyrazolopyridine+Inhibitors+of+B-RAF%28V600E%29.+Part+4%3A+Rational+Design+and+Kinase+Selectivity+Profile+of+Cell+Potent+Type+II+Inhibitors&doi=10.1016%2Fj.bmcl.2012.08.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26atitle%3DPyrazolopyridine%2520Inhibitors%2520of%2520B-RAF%2528V600E%2529.%2520Part%25204%253A%2520Rational%2520Design%2520and%2520Kinase%2520Selectivity%2520Profile%2520of%2520Cell%2520Potent%2520Type%2520II%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6237%26epage%3D6241%26doi%3D10.1016%2Fj.bmcl.2012.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jambrina, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilkington, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybakova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodenko, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchete, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosta, E.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1002/anie.201509272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1002%2Fanie.201509272" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=983-986&author=P.+G.+Jambrinaauthor=N.+Rauchauthor=R.+Pilkingtonauthor=K.+Rybakovaauthor=L.+K.+Nguyenauthor=B.+N.+Kholodenkoauthor=N.+Bucheteauthor=W.+Kolchauthor=E.+Rosta&title=Phosphorylation+of+RAF+Kinase+Dimers+Drives+Conformational+Changes+that+Facilitate+Transactivation&doi=10.1002%2Fanie.201509272"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201509272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201509272%26sid%3Dliteratum%253Aachs%26aulast%3DJambrina%26aufirst%3DP.%2BG.%26aulast%3DRauch%26aufirst%3DN.%26aulast%3DPilkington%26aufirst%3DR.%26aulast%3DRybakova%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DL.%2BK.%26aulast%3DKholodenko%26aufirst%3DB.%2BN.%26aulast%3DBuchete%26aufirst%3DN.%26aulast%3DKolch%26aufirst%3DW.%26aulast%3DRosta%26aufirst%3DE.%26atitle%3DPhosphorylation%2520of%2520RAF%2520Kinase%2520Dimers%2520Drives%2520Conformational%2520Changes%2520that%2520Facilitate%2520Transactivation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D983%26epage%3D986%26doi%3D10.1002%2Fanie.201509272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&issue=6&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+Activation+of+the+RAF-ERK+Signaling+Pathway+by+Oncogenic+Mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lgZNKCIXY8Vmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520Activation%2520of%2520the%2520RAF-ERK%2520Signaling%2520Pathway%2520by%2520Oncogenic%2520Mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26issue%3D6%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlattl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalkuhl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1158%2F1535-7163.MCT-15-0617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=26916115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=354-365&issue=3&author=I.+C.+Waizeneggerauthor=A.+Baumauthor=S.+Steurerauthor=H.+Stadtmullerauthor=G.+Baderauthor=O.+Schaafauthor=P.+Garin-Chesaauthor=A.+Schlattlauthor=N.+Schweiferauthor=C.+Haslingerauthor=F.+Colbatzkyauthor=S.+Mousaauthor=A.+Kalkuhlauthor=N.+Krautauthor=G.+R.+Adolf&title=A+Novel+RAF+Kinase+Inhibitor+with+DFG-Out-Binding+Mode%3A+High+Efficacy+in+BRAF-Mutant+Tumor+Xenograft+Models+in+the+Absence+of+Normal+Tissue+Hyperproliferation&doi=10.1158%2F1535-7163.MCT-15-0617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span></div><div class="casAuthors">Waizenegger, Irene C.; Baum, Anke; Steurer, Steffen; Stadtmuller, Heinz; Bader, Gerd; Schaaf, Otmar; Garin-Chesa, Pilar; Schlattl, Andreas; Schweifer, Norbert; Haslinger, Christian; Colbatzky, Florian; Mousa, Sien; Kalkuhl, Arno; Kraut, Norbert; Adolf, Gunther R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">354-365</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BI 882370 is a highly potent and selective RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase.  The compd. inhibited proliferation of human BRAF-mutant melanoma cells with 100× higher potency (1-10 nmol/L) than vemurafenib, whereas wild-type cells were not affected at 1,000 nmol/L.  BI 882370 administered orally was efficacious in multiple mouse models of BRAF-mutant melanomas and colorectal carcinomas, and at 25 mg/kg twice daily showed superior efficacy compared with vemurafenib, dabrafenib, or trametinib (dosed to provide exposures reached in patients).  To model drug resistance, A375 melanoma-bearing mice were initially treated with vemurafenib; all tumors responded with regression, but the majority subsequently resumed growth.  Trametinib did not show any efficacy in this progressing population.  BI 882370 induced tumor regression; however, resistance developed within 3 wk.  BI 882370 in combination with trametinib resulted in more pronounced regressions, and resistance was not obsd. during 5 wk of second-line therapy.  Importantly, mice treated with BI 882370 did not show any body wt. loss or clin. signs of intolerability, and no pathol. changes were obsd. in several major organs investigated, including skin.  Furthermore, a pilot study in rats (up to 60 mg/kg daily for 2 wk) indicated lack of toxicity in terms of clin. chem., hematol., pathol., and toxicogenomics.  Our results indicate the feasibility of developing novel compds. that provide an improved therapeutic window compared with first-generation BRAF inhibitors, resulting in more pronounced and long-lasting pathway suppression and thus improved efficacy.  Mol Cancer Ther; 15(3); 354-65. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmtRl_zbyDibVg90H21EOLACvtfcHk0liMdXP-JPxPSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D&md5=e35140e31364622de51538b99618001a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0617%26sid%3Dliteratum%253Aachs%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DStadtmuller%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSchaaf%26aufirst%3DO.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DSchlattl%26aufirst%3DA.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DMousa%26aufirst%3DS.%26aulast%3DKalkuhl%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DA%2520Novel%2520RAF%2520Kinase%2520Inhibitor%2520with%2520DFG-Out-Binding%2520Mode%253A%2520High%2520Efficacy%2520in%2520BRAF-Mutant%2520Tumor%2520Xenograft%2520Models%2520in%2520the%2520Absence%2520of%2520Normal%2520Tissue%2520Hyperproliferation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D3%26spage%3D354%26epage%3D365%26doi%3D10.1158%2F1535-7163.MCT-15-0617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bregman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babij, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnahan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Purinylpyridinylamino-Based DFG-In/αC-Helix-Out B-RAF Inhibitors: Applying Mutant Versus Wild-Type B-RAF Selectivity Indices for Compound Profiling</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2215</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.bmc.2016.03.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=27085672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVarsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2215-2234&author=L.+Liuauthor=M.+R.+Leeauthor=J.+L.+Kimauthor=D.+A.+Whittingtonauthor=H.+Bregmanauthor=Z.+Huaauthor=R.+T.+Lewisauthor=M.+W.+Martinauthor=N.+Nishimuraauthor=M.+Potashmanauthor=K.+Yangauthor=S.+Yiauthor=K.+R.+Vaidaauthor=L.+F.+Epsteinauthor=C.+Babijauthor=M.+Fernandoauthor=J.+Carnahanauthor=M.+H.+Norman&title=Purinylpyridinylamino-Based+DFG-In%2F%CE%B1C-Helix-Out+B-RAF+Inhibitors%3A+Applying+Mutant+Versus+Wild-Type+B-RAF+Selectivity+Indices+for+Compound+Profiling&doi=10.1016%2Fj.bmc.2016.03.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling</span></div><div class="casAuthors">Liu, Longbin; Lee, Matthew R.; Kim, Joseph L.; Whittington, Douglas A.; Bregman, Howard; Hua, Zihao; Lewis, Richard T.; Martin, Matthew W.; Nishimura, Nobuko; Potashman, Michele; Yang, Kevin; Yi, Shuyan; Vaida, Karina R.; Epstein, Linda F.; Babij, Carol; Fernando, Manory; Carnahan, Josette; Norman, Mark H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2215-2234</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">One of the challenges for targeting B-RafV600E with small mol. inhibitors had been achieving adequate selectivity over the wild-type protein B-RafWT, as inhibition of the latter has been assocd. with hyperplasia in normal tissues.  Recent studies suggest that B-Raf inhibitors inducing the 'DFG-in/αC-helix-out' conformation (Type IIB) likely will exhibit improved selectivity for B-RafV600E.  To explore this hypothesis, we transformed Type IIA inhibitor (1) into a series of Type IIB inhibitors (sulfonamides and sulfamides 4-6) and examd. the SAR.  Three selectivity indexes were introduced to facilitate the analyses: the B-RafV600E/B-RafWT biochem. (bS), cellular (cS) selectivity, and the phospho-ERK activation (pA).  Our data indicates that α-branched sulfonamides and sulfamides show higher selectivities than the linear derivs.  We rationalized this finding based on anal. of structural information from the literature and provided evidence for a monomeric B-Raf-inhibitor complex previously hypothesized to be responsible for the desired B-RafV600E selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2yyHmmmdGKrVg90H21EOLACvtfcHk0liMdXP-JPxPSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVarsbc%253D&md5=5829f989b56e20539a03b78f376017c4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.055%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DBregman%26aufirst%3DH.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYi%26aufirst%3DS.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DPurinylpyridinylamino-Based%2520DFG-In%252F%25CE%25B1C-Helix-Out%2520B-RAF%2520Inhibitors%253A%2520Applying%2520Mutant%2520Versus%2520Wild-Type%2520B-RAF%2520Selectivity%2520Indices%2520for%2520Compound%2520Profiling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D2215%26epage%3D2234%26doi%3D10.1016%2Fj.bmc.2016.03.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz-Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span> <span> </span><span class="NLM_article-title">Ligand Recognition by E- and P-Selectin: Chemoenzymatic Synthesis and Inhibitory Activity of Bivalent Sialyl Lewis x Derivatives and Sialyl Lewis x Carboxylic Acid</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5137</span>– <span class="NLM_lpage">5143</span>, <span class="refDoi"> DOI: 10.1021/jo980350s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo980350s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1998&pages=5137-5143&author=V.+Wittmannauthor=S.+Takayamaauthor=K.+W.+Gongauthor=G.+Weitz-Schmidtauthor=C.+Wong&title=Ligand+Recognition+by+E-+and+P-Selectin%3A+Chemoenzymatic+Synthesis+and+Inhibitory+Activity+of+Bivalent+Sialyl+Lewis+x+Derivatives+and+Sialyl+Lewis+x+Carboxylic+Acid&doi=10.1021%2Fjo980350s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjo980350s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo980350s%26sid%3Dliteratum%253Aachs%26aulast%3DWittmann%26aufirst%3DV.%26aulast%3DTakayama%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DK.%2BW.%26aulast%3DWeitz-Schmidt%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DC.%26atitle%3DLigand%2520Recognition%2520by%2520E-%2520and%2520P-Selectin%253A%2520Chemoenzymatic%2520Synthesis%2520and%2520Inhibitory%2520Activity%2520of%2520Bivalent%2520Sialyl%2520Lewis%2520x%2520Derivatives%2520and%2520Sialyl%2520Lewis%2520x%2520Carboxylic%2520Acid%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1998%26volume%3D63%26spage%3D5137%26epage%3D5143%26doi%3D10.1021%2Fjo980350s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mohammed S. Abdel-Maksoud, Mohammed I. El-Gamal, Bong S. Lee, Mahmoud M. Gamal El-Din, Hong R. Jeon, Dow Kwon, Usama M. Ammar, Karim I. Mersal, Eslam M. H. Ali, Kyung-Tae Lee, Kyung Ho Yoo, Dong Keun Han, Jae Kyun Lee, Garam Kim, Hong Seok Choi, Young Jik Kwon, Kwan Hyi Lee, <span class="NLM_string-name hlFld-ContribAuthor">Chang Hyun Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6877-6901. <a href="https://doi.org/10.1021/acs.jmedchem.1c00230" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00230%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNew%252BImidazo%25255B2%25252C1-b%25255Dthiazole%252BDerivatives%252Bas%252BPotent%252BPan-RAF%252BInhibitors%252Bwith%252BPromising%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAnti-melanoma%252BActivity%26aulast%3DAbdel-Maksoud%26aufirst%3DMohammed%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D05022021%26date%3D17052021%26volume%3D64%26issue%3D10%26spage%3D6877%26epage%3D6901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hon Yan Kelvin  Yip</span>, <span class="hlFld-ContribAuthor ">Antonella  Papa</span>. </span><span class="cited-content_cbyCitation_article-title">Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (3)
                                     , 659. <a href="https://doi.org/10.3390/cells10030659" title="DOI URL">https://doi.org/10.3390/cells10030659</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10030659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10030659%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DSignaling%252BPathways%252Bin%252BCancer%25253A%252BTherapeutic%252BTargets%25252C%252BCombinatorial%252BTreatments%25252C%252Band%252BNew%252BDevelopments%26aulast%3DYip%26aufirst%3DHon%2BYan%2BKelvin%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D3%26spage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas J.  Cope</span>, <span class="hlFld-ContribAuthor ">Borna  Novak</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Liu</span>, <span class="hlFld-ContribAuthor ">Maria  Cavallo</span>, <span class="hlFld-ContribAuthor ">Amber Y.  Gunderwala</span>, <span class="hlFld-ContribAuthor ">Matthew  Connolly</span>, <span class="hlFld-ContribAuthor ">Zhihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2020,</strong> <em>295 </em>
                                    (8)
                                     , 2407-2420. <a href="https://doi.org/10.1074/jbc.RA119.011536" title="DOI URL">https://doi.org/10.1074/jbc.RA119.011536</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.011536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.011536%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DAnalyses%252Bof%252Bthe%252Boncogenic%252BBRAFD594G%252Bvariant%252Breveal%252Ba%252Bkinase-independent%252Bfunction%252Bof%252BBRAF%252Bin%252Bactivating%252BMAPK%252Bsignaling%26aulast%3DCope%26aufirst%3DNicholas%2BJ.%26date%3D2020%26volume%3D295%26issue%3D8%26spage%3D2407%26epage%3D2420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas  Cope</span>, <span class="hlFld-ContribAuthor ">Borna  Novak</span>, <span class="hlFld-ContribAuthor ">Christine  Candelora</span>, <span class="hlFld-ContribAuthor ">Kenneth  Wong</span>, <span class="hlFld-ContribAuthor ">Maria  Cavallo</span>, <span class="hlFld-ContribAuthor ">Amber  Gunderwala</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Liu</span>, <span class="hlFld-ContribAuthor ">Yana  Li</span>, <span class="hlFld-ContribAuthor ">Zhihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Biochemical Characterization of Full‐Length Oncogenic BRAF
              V600E
              together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2019,</strong> <em>20 </em>
                                    (22)
                                     , 2850-2861. <a href="https://doi.org/10.1002/cbic.201900266" title="DOI URL">https://doi.org/10.1002/cbic.201900266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.201900266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.201900266%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DBiochemical%252BCharacterization%252Bof%252BFull%2525E2%252580%252590Length%252BOncogenic%252BBRAF%252BV600E%252Btogether%252Bwith%252BMolecular%252BDynamics%252BSimulations%252BProvide%252BInsight%252Binto%252Bthe%252BActivation%252Band%252BInhibition%252BMechanisms%252Bof%252BRAF%252BKinases%26aulast%3DCope%26aufirst%3DNicholas%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D22%26spage%3D2850%26epage%3D2861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paola  Savoia</span>, <span class="hlFld-ContribAuthor ">Paolo  Fava</span>, <span class="hlFld-ContribAuthor ">Filippo  Casoni</span>, <span class="hlFld-ContribAuthor ">Ottavio  Cremona</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the ERK Signaling Pathway in Melanoma. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (6)
                                     , 1483. <a href="https://doi.org/10.3390/ijms20061483" title="DOI URL">https://doi.org/10.3390/ijms20061483</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20061483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20061483%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTargeting%252Bthe%252BERK%252BSignaling%252BPathway%252Bin%252BMelanoma%26aulast%3DSavoia%26aufirst%3DPaola%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D6%26spage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas  Cope</span>, <span class="hlFld-ContribAuthor ">Christine  Candelora</span>, <span class="hlFld-ContribAuthor ">Kenneth  Wong</span>, <span class="hlFld-ContribAuthor ">Sujeet  Kumar</span>, <span class="hlFld-ContribAuthor ">Haihan  Nan</span>, <span class="hlFld-ContribAuthor ">Michael  Grasso</span>, <span class="hlFld-ContribAuthor ">Borna  Novak</span>, <span class="hlFld-ContribAuthor ">Yana  Li</span>, <span class="hlFld-ContribAuthor ">Ronen  Marmorstein</span>, <span class="hlFld-ContribAuthor ">Zhihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism of BRAF Activation through Biochemical Characterization of the Recombinant Full-Length Protein. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2018,</strong> <em>19 </em>
                                    (18)
                                     , 1988-1997. <a href="https://doi.org/10.1002/cbic.201800359" title="DOI URL">https://doi.org/10.1002/cbic.201800359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.201800359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.201800359%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DMechanism%252Bof%252BBRAF%252BActivation%252Bthrough%252BBiochemical%252BCharacterization%252Bof%252Bthe%252BRecombinant%252BFull-Length%252BProtein%26aulast%3DCope%26aufirst%3DNicholas%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D18%26spage%3D1988%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of TAK632 bound BRAF and rationale for linked TAK inhibitors. (a) Structure of BRAF<sup>WT</sup>/TAK632 (accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>), highlighting the exposed cyclopropane ring. (b) Structure of monomeric TAK632 and where it interacts with residue Cys532 of BRAF. (c) Initial scaffold for dimeric TAK inhibitors where n equals the number of ethylene glycol moiety groups present. (d) Alignment of BRAF<sup>WT</sup>/TAK632 (pink and gray) with BRAF<sup>V600E</sup>/Vem-BisAmide-2 structure (blue) (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2">5JT2</a>). (e). Preparation of dimeric TAK-n-TAK structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Potency of first-generation dimeric TAK inhibitors. (a) Dose response curves of dimeric TAK inhibitors against BRAF<sup>WT</sup> with TAK632 as a control. Calculated IC<sub>50</sub> values are indicated. The experiments were performed in triplicate with ± SEM shown. The 95% confidence intervals are TAK632 (1.47–7.47 nM), TAK-2-TAK (69.6–249 nM), TAK-4-TAK 48.4–168 nM), TAK-0-TAK (347–832 nM), TAK-3-TAK (351–1.08 μM), and TAK-6-TAK (277–1.94 μM). (b) Dose response curves of dimeric TAK inhibitors against BRAF<sup>V600E</sup> with TAK632 as a control, carried out in triplicate with ± SEM shown. The 95% confidence intervals are TAK632 (2.67–7.45 nM), TAK-2-TAK (47.5–115 nM), TAK-4-TAK (59.7–91.1 nM), TAK-0-TAK (323–549 nM), TAK-3-TAK (128–219 nM), and TAK-6-TAK (199–621 nM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Sedimentation velocity experiments of dimeric TAK Inhibitors. (a) BRAF<sup>R509H</sup> (10 μM) in the absence and presence of TAK632 and TAK-2-TAK inhibitor at different concentrations. (b) BRAFR<sup>509H</sup> (12 μM) in the absence and presence of TAK632 and TAK-4-TAK inhibitor at different concentrations. (c) BRAF<sup>R509H</sup> (12 μM) in the absence and presence of TAK632, TAK-3-TAK, and TAK-6-TAK inhibitors at 20 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Sedimentation velocity and sedimentation equilibrium experiments of dimeric TAK Inhibitors. (a) BRAF<sup>R509H</sup> (20 μM) in the absence and presence of TAK632 and TAK-4-TAK inhibitor at different concentrations. (b) BRAF<sup>WT</sup> (10 μM) in the absence and presence of TAK632 and TAK-2-TAK. (c) BRAF<sup>V600E</sup> (10 μM) in the absence and presence of TAK632 and TAK-2-TAK and TAK-4-TAK inhibitors at different concentrations. (d) Log plots of sedimentation equilibrium experiments showing theoretical monomer (purple) and theoretical dimer (blue) slopes of BRAF compared to BRAF<sup>R509H</sup> in the absence and presence of TAK632 and dimeric TAK-4-TAK at a 2:1 molar ratio of inhibitor to protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Biochemical and biophysical properties of TAK-linker compounds. (a) Preparation of monomeric TAK control compounds, TAK-L (TAK with linker) and TAK-L-C (TAK with linker and cap). (b) Dose response curves of TAK control compounds along with dimeric TAK-2-TAK and TAK-4-TAK and TAK632 against BRAF<sup>WT</sup>. Calculated IC<sub>50</sub> values are indicated. The experiments are performed in duplicate with ± SEM shown. 95% confidence intervals are TAK-L (3.33–9.91 nM), TAK-L-C (10.3–40.2 nM), TAK-2-TAK (50.2–151 nM), TAK-4-TAK (56.7–129 nM), and TAK632 (3.32–15.2 nM). (c) Sedimentation velocity experiments with BRAF<sup>R509H</sup> (15 μM) in the presence of TAK-L, TAK-L-C, and TAK-2-TAK at 20 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Determination of dimeric TAK inhibitor binding modes to BRAF. (a) Limited proteolysis experiment of BRAF<sup>WT</sup> in the presence and absence of 200 μM inhibitors after exposure to trypsin for 30 min (lanes 1–5), and lane 6 shows BRAF<sup>WT</sup> without ligand or trypsin. (b) Differential scanning calorimetry (DSC) experiments in which BRAF<sup>WT</sup> is heated in the presence and absence of inhibitors ranging in concentration from 25 to 250 μM. Melting temperatures are as follows: 125 μM TAK632, 68.74 °C; 125 μM TAK-L-C, 63.29 °C; 75 μM TAK-2-TAK, 38.37 °C, 58.65 °C; 125 μM TAK-2-TAK, 38.72 °C, 59.6 °C; 250 μM TAK-2-TAK, 40.08 °C, 62.64 °C; no ligand, 37.84 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. BRAF<sup>R509H</sup> dimer interface via TAK632 binding. (a) Overlay of BRAF<sup>WT</sup>/TAK632 (light pink and magenta), BRAF<sup>V600E</sup>/AZ628 (light gray and dark gray), BRAF<sup>R509H</sup>/AZ628 (blue and teal), and BRAF<sup>V600E</sup>/vemurafenib (yellow) structures, highlighting the shift within the αC-in position. Different subunits of the crystal structures are denoted with subscript 1 and 2, respectively. (b) Overlay of BRAF<sup>WT</sup>/TAK632 (light pink, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>), BRAF<sup>V600E</sup>/AZ628 (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R">4G9R</a>), and BRAF<sup>R509H</sup>/AZ628 (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW">4RZW</a>), highlighting a shift in the W450 residue in the BRAF<sup>R509H</sup> structure. (c) Crystal structure of BRAF<sup>R509H</sup> bound to AZ628 demonstrates that W450 forms π-stacking interactions with His509. (d) Residue D448 accompanies the shift in the W450 residue, hydrogen bonding with the other static W450. (e) R506 residues in both subunits of BRAF<sup>WT</sup>/TAK632 (light pink and magenta), BRAF<sup>V600E</sup>/AZ628 (light gray and dark gray), and BRAF<sup>R509H</sup>/AZ628 (blue and teal) aligned with one subunit of BRAF<sup>V600E</sup>/vemurafenib (yellow), demonstrating “in” and “out” positions of R506. (f). W450 lies within close proximity of R506 and the W450 in BRAF<sup>R509H</sup>/AZ628 shifts closer to R506.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Sedimentation velocity experiments of dimerization mutants and αC-in/αC-out inhibitors. (a) Sedimentation velocity experiments of BRAF<sup>R509H</sup>, BRAF<sup>R506A</sup>, and BRAF<sup>W450A</sup> in the absence and presence of TAK632 at 15–25 μM. (b) Sedimentation velocity experiments of BRAF<sup>R509H</sup>, BRAF<sup>R506A/R509H</sup>, BRAF<sup>W450A/R509H</sup>, and BRAF<sup>R506A/W450A/R509H</sup> in the absence and presence of TAK at 25 μM. (c) Sedimentation velocity experiments of BRAF<sup>R509H</sup> without inhibitor and with 20 μM of both TAK632 and sorafenib. (d) Sedimentation velocity experiments of BRAF<sup>WT</sup> and BRAF<sup>V600E</sup> with 15 μM vemurafenib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/medium/jm-2018-00499n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Superposition of BRAF<sup>V600E</sup>/Vem-BisAmide-2 with BRAFWT/TAK632. (a) Overlay of BRAF<sup>WT</sup> cocrystallized with TAK632 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP">4KSP</a>) overlaid with the αC-out/αC-out “face-to-face” dimer induced by Vem-BisAmide-2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2">5JT2</a>). (b) Comparison of activation segment of BRAF<sup>V600E</sup> bound to Vem-BisAmide-2 in an active conformation (cyan) and the activation segment of BRAF<sup>WT</sup> bound to TAK632 in an inactive conformation (magenta), protruding into the other molecule of the “face-to-face” dimer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-11/acs.jmedchem.8b00499/20180608/images/large/jm-2018-00499n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00499&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wellbrock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasarides, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">The RAF Proteins Take Centre Stage</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1038/nrm1498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnrm1498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=15520807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFemsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=875-885&author=C.+Wellbrockauthor=M.+Karasaridesauthor=R.+Marais&title=The+RAF+Proteins+Take+Centre+Stage&doi=10.1038%2Fnrm1498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF proteins take center stage</span></div><div class="casAuthors">Wellbrock, Claudia; Karasarides, Maria; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">875-885</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since their discovery over 20 years ago, the RAF proteins have been intensely studied.  For most of that time, the focus of the field has been the C-RAF isoform and its role as an effector of the RAS proteins.  However, a report that implicates B-RAF in human cancer has highlighted the importance of all members of this protein kinase family and recent studies have uncovered intriguing new data relating to their complex regulation and biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvN4GggcdfU7Vg90H21EOLACvtfcHk0ljj1lw6xEK-Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFemsLs%253D&md5=95f0a579b4c852fbe80a54befb88b052</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm1498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1498%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DKarasarides%26aufirst%3DM.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DThe%2520RAF%2520Proteins%2520Take%2520Centre%2520Stage%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D875%26epage%3D885%26doi%3D10.1038%2Fnrm1498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignell, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clegg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woffendin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmidou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mould, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayatilake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusterson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard-Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenevix-Trench, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seigler, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Mutations of the BRAF Gene in Human Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.1038/nature00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+Gene+in+Human+Cancer&doi=10.1038%2Fnature00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lgx6vIG2uo9oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520Gene%2520in%2520Human%2520Cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954%26doi%3D10.1038%2Fnature00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikenoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikiba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijichi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aragaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omata, M.</span></span> <span> </span><span class="NLM_article-title">Functional Analysis of Mutations Within the Kinase Activation Segment of B-Raf in Human Colorectal Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8132</span>– <span class="NLM_lpage">8137</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=8132-8137&author=T.+Ikenoueauthor=Y.+Hikibaauthor=F.+Kanaiauthor=Y.+Tanakaauthor=J.+Imamuraauthor=T.+Imamuraauthor=M.+Ohtaauthor=H.+Ijichiauthor=K.+Tateishiauthor=T.+Kawakamiauthor=J.+Aragakiauthor=M.+Matsumuraauthor=T.+Kawabeauthor=M.+Omata&title=Functional+Analysis+of+Mutations+Within+the+Kinase+Activation+Segment+of+B-Raf+in+Human+Colorectal+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIkenoue%26aufirst%3DT.%26aulast%3DHikiba%26aufirst%3DY.%26aulast%3DKanai%26aufirst%3DF.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DJ.%26aulast%3DImamura%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DIjichi%26aufirst%3DH.%26aulast%3DTateishi%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DT.%26aulast%3DAragaki%26aufirst%3DJ.%26aulast%3DMatsumura%26aufirst%3DM.%26aulast%3DKawabe%26aufirst%3DT.%26aulast%3DOmata%26aufirst%3DM.%26atitle%3DFunctional%2520Analysis%2520of%2520Mutations%2520Within%2520the%2520Kinase%2520Activation%2520Segment%2520of%2520B-Raf%2520in%2520Human%2520Colorectal%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D8132%26epage%3D8137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical Efficacy Of A RAF Inhibitor Needs A Broad Target Blockade In BRAF-Mutant Melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">596</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+Efficacy+Of+A+RAF+Inhibitor+Needs+A+Broad+Target+Blockade+In+BRAF-Mutant+Melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520Efficacy%2520Of%2520A%2520RAF%2520Inhibitor%2520Needs%2520A%2520Broad%2520Target%2520Blockade%2520In%2520BRAF-Mutant%2520Melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rheault, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjabeng, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossanese, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnone, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smitheman, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane-Carson, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of Dabrafenib: A Selective Inhibitor of RAF Kinases with Antitumor Activity Against B-RAF Driven Tumors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/ml4000063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=358-362&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithemanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G.+Mossauthor=D.+E.+Uehling&title=Discovery+of+Dabrafenib%3A+A+Selective+Inhibitor+of+RAF+Kinases+with+Antitumor+Activity+Against+B-RAF+Driven+Tumors&doi=10.1021%2Fml4000063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520Dabrafenib%253A%2520A%2520Selective%2520Inhibitor%2520of%2520RAF%2520Kinases%2520with%2520Antitumor%2520Activity%2520Against%2520B-RAF%2520Driven%2520Tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D358%26epage%3D362%26doi%3D10.1021%2Fml4000063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mutated, Activated BRAF in Metastatic Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&issue=9&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+Mutated%2C+Activated+BRAF+in+Metastatic+Melanoma&doi=10.1056%2FNEJMoa1002011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0liBF1YNDI8Idw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520Mutated%252C%2520Activated%2520BRAF%2520in%2520Metastatic%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D9%26spage%3D809%26epage%3D819%26doi%3D10.1056%2FNEJMoa1002011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nazarian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sazegar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span> <span> </span><span class="NLM_article-title">Melanomas Acquire Resistance to BRAF(V600E) Inhibition by RTK or N-RAS Upregulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span> (<span class="NLM_issue">7326</span>),  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1038/nature09626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature09626" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=973-977&issue=7326&author=R.+Nazarianauthor=H.+Shiauthor=Q.+Wangauthor=X.+Kongauthor=R.+C.+Koyaauthor=H.+Leeauthor=Z.+Chenauthor=M.+K.+Leeauthor=N.+Attarauthor=H.+Sazegarauthor=T.+Chodonauthor=S.+F.+Nelsonauthor=G.+McArthurauthor=J.+A.+Sosmanauthor=A.+Ribasauthor=R.+S.+Lo&title=Melanomas+Acquire+Resistance+to+BRAF%28V600E%29+Inhibition+by+RTK+or+N-RAS+Upregulation&doi=10.1038%2Fnature09626"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature09626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09626%26sid%3Dliteratum%253Aachs%26aulast%3DNazarian%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DM.%2BK.%26aulast%3DAttar%26aufirst%3DN.%26aulast%3DSazegar%26aufirst%3DH.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DMelanomas%2520Acquire%2520Resistance%2520to%2520BRAF%2528V600E%2529%2520Inhibition%2520by%2520RTK%2520or%2520N-RAS%2520Upregulation%26jtitle%3DNature%26date%3D2010%26volume%3D468%26issue%3D7326%26spage%3D973%26epage%3D977%26doi%3D10.1038%2Fnature09626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Prime Wild-Type RAF to Activate the MAPK Pathway and Enhance Growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&issue=7287&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+Inhibitors+Prime+Wild-Type+RAF+to+Activate+the+MAPK+Pathway+and+Enhance+Growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0liBF1YNDI8Idw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520Inhibitors%2520Prime%2520Wild-Type%2520RAF%2520to%2520Activate%2520the%2520MAPK%2520Pathway%2520and%2520Enhance%2520Growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors Transactivate RAF Dimers and ERK Signaling in Cells with Wild-Type BRAF</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nature08902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&issue=7287&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+Inhibitors+Transactivate+RAF+Dimers+and+ERK+Signaling+in+Cells+with+Wild-Type+BRAF&doi=10.1038%2Fnature08902"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520Inhibitors%2520Transactivate%2520RAF%2520Dimers%2520and%2520ERK%2520Signaling%2520in%2520Cells%2520with%2520Wild-Type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D427%26epage%3D430%26doi%3D10.1038%2Fnature08902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stites, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germino, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meharena, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stork, P. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornev, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span> <span> </span><span class="NLM_article-title">Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1036</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2013.07.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.cell.2013.07.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=23993095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGru77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2013&pages=1036-1046&author=J.+Huauthor=E.+C.+Stitesauthor=H.+Yuauthor=E.+A.+Germinoauthor=H.+S.+Meharenaauthor=P.+J.+S.+Storkauthor=A.+P.+Kornevauthor=S.+S.+Taylorauthor=A.+S.+Shaw&title=Allosteric+Activation+of+Functionally+Asymmetric+RAF+Kinase+Dimers&doi=10.1016%2Fj.cell.2013.07.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers</span></div><div class="casAuthors">Hu, Jiancheng; Stites, Edward C.; Yu, Haiyang; Germino, Elizabeth A.; Meharena, Hiruy S.; Stork, Philip J. S.; Kornev, Alexandr P.; Taylor, Susan S.; Shaw, Andrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1036-1046</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although RAF kinases are crit. for controlling cell growth, their mechanism of activation is incompletely understood.  Recently, dimerization was shown to be important for activation.  Here we show that the dimer is functionally asym. with one kinase functioning as an activator to stimulate activity of the partner, receiver kinase.  The activator kinase did not require kinase activity but did require N-terminal phosphorylation that functioned allosterically to induce cis-autophosphorylation of the receiver kinase.  Based on modeling of the hydrophobic spine assembly, we also engineered a constitutively active mutant that was independent of Ras, dimerization, and activation-loop phosphorylation.  As N-terminal phosphorylation of BRAF is constitutive, BRAF initially functions to activate CRAF.  N-terminal phosphorylation of CRAF was dependent on MEK, suggesting a feedback mechanism and explaining a key difference between BRAF and CRAF.  Our work illuminates distinct steps in RAF activation that function to assemble the active conformation of the RAF kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU3Cusz6x-4bVg90H21EOLACvtfcHk0liTayail2VUxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGru77N&md5=e8f5cfdfeb1c9f974b719e8c9716b687</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.07.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.07.046%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DStites%26aufirst%3DE.%2BC.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DGermino%26aufirst%3DE.%2BA.%26aulast%3DMeharena%26aufirst%3DH.%2BS.%26aulast%3DStork%26aufirst%3DP.%2BJ.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26atitle%3DAllosteric%2520Activation%2520of%2520Functionally%2520Asymmetric%2520RAF%2520Kinase%2520Dimers%26jtitle%3DCell%26date%3D2013%26volume%3D154%26spage%3D1036%26epage%3D1046%26doi%3D10.1016%2Fj.cell.2013.07.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajakulendran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefrançois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">A Dimerization-Dependent Mechanism Drives RAF Catalytic Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>461</i></span> (<span class="NLM_issue">7263</span>),  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1038/nature08314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature08314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=19727074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOmu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2009&pages=542-545&issue=7263&author=T.+Rajakulendranauthor=M.+Sahmiauthor=M.+Lefran%C3%A7oisauthor=F.+Sicheriauthor=M.+Therrien&title=A+Dimerization-Dependent+Mechanism+Drives+RAF+Catalytic+Activation&doi=10.1038%2Fnature08314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A dimerization-dependent mechanism drives RAF catalytic activation</span></div><div class="casAuthors">Rajakulendran, Thanashan; Sahmi, Malha; Lefrancois, Martin; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">7263</span>),
    <span class="NLM_cas:pages">542-545</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ERK (extracellular signal-regulated kinase) pathway is an evolutionarily conserved signal transduction module that controls cellular growth, differentiation and survival.  Activation of receptor tyrosine kinases (RTKs) by the binding of growth factors initiates GTP loading of RAS, which triggers the initial steps in the activation of the ERK pathway by modulating RAF family kinase function.  Once activated, RAF participates in a sequential cascade of phosphorylation events that activate MEK, and in turn ERK.  Unbridled signalling through the ERK pathway caused by activating mutations in RTKs, RAS or RAF has been linked to several human cancers.  Of note, one member of the RAF family, BRAF, is the most frequently mutated oncogene in the kinase superfamily.  Not surprisingly, there has been a colossal effort to understand the underlying regulation of this family of kinases.  In particular, the process by which the RAF kinase domain becomes activated towards its substrate MEK remains of topical interest.  Here, using Drosophila Schneider S2 cells, we demonstrate that RAF catalytic function is regulated in response to a specific mode of dimerization of its kinase domain, which we term the side-to-side dimer.  Moreover, we find that the RAF-related pseudo-kinase KSR (kinase suppressor of Ras) also participates in forming side-to-side heterodimers with RAF and can thereby trigger RAF activation.  This mechanism provides an elegant explanation for the longstanding conundrum about RAF catalytic activation and also provides an explanation for the capacity of KSR, despite lacking catalytic function, to directly mediate RAF activation.  We also show that RAF side-to-side dimer formation is essential for aberrant signalling by oncogenic BRAF mutants, and identify an oncogenic mutation that acts specifically by promoting side-to-side dimerization.  Together, our data identify the side-to-side dimer interface of RAF as a potential therapeutic target for intervention in BRAF-dependent tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbnxNSbvudjbVg90H21EOLACvtfcHk0liTayail2VUxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOmu7fI&md5=2248d71ce37a2bac4e508a1097e95cba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature08314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08314%26sid%3Dliteratum%253Aachs%26aulast%3DRajakulendran%26aufirst%3DT.%26aulast%3DSahmi%26aufirst%3DM.%26aulast%3DLefran%25C3%25A7ois%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DA%2520Dimerization-Dependent%2520Mechanism%2520Drives%2520RAF%2520Catalytic%2520Activation%26jtitle%3DNature%26date%3D2009%26volume%3D461%26issue%3D7263%26spage%3D542%26epage%3D545%26doi%3D10.1038%2Fnature08314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidorn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression Through CRAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=S.+J.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-Dead+BRAF+and+Oncogenic+RAS+Cooperate+to+Drive+Tumor+Progression+Through+CRAF&doi=10.1016%2Fj.cell.2009.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0liTayail2VUxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DS.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-Dead%2520BRAF%2520and%2520Oncogenic%2520RAS%2520Cooperate%2520to%2520Drive%2520Tumor%2520Progression%2520Through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.cell.2009.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janakiraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misteli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitor Resistance is Mediated by Dimerization of Aberrantly Spliced BRAF(V600E)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>480</i></span> (<span class="NLM_issue">7377</span>),  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1038/nature10662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature10662" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=387-390&issue=7377&author=P.+I.+Poulikakosauthor=Y.+Persaudauthor=M.+Janakiramanauthor=X.+Kongauthor=C.+Ngauthor=G.+Moriceauauthor=H.+Shiauthor=M.+Atefiauthor=B.+Titzauthor=M.+T.+Gabayauthor=M.+Saltonauthor=K.+B.+Dahlmanauthor=M.+Tadiauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=M.+C.+Kelleyauthor=T.+Misteliauthor=P.+B.+Chapmanauthor=J.+A.+Sosmanauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=N.+Rosenauthor=D.+B.+Solit&title=RAF+Inhibitor+Resistance+is+Mediated+by+Dimerization+of+Aberrantly+Spliced+BRAF%28V600E%29&doi=10.1038%2Fnature10662"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10662%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DJanakiraman%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DTitz%26aufirst%3DB.%26aulast%3DGabay%26aufirst%3DM.%2BT.%26aulast%3DSalton%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DRAF%2520Inhibitor%2520Resistance%2520is%2520Mediated%2520by%2520Dimerization%2520of%2520Aberrantly%2520Spliced%2520BRAF%2528V600E%2529%26jtitle%3DNature%26date%3D2011%26volume%3D480%26issue%3D7377%26spage%3D387%26epage%3D390%26doi%3D10.1038%2Fnature10662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nespi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanftner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">RAF Inhibitors that Evade Paradoxical MAPK Pathway Activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>526</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1038/nature14982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnature14982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=26466569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWitLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=583-586&author=C.+Zhangauthor=W.+Spevakauthor=Y.+Zhangauthor=E.+A.+Burtonauthor=Y.+Maauthor=G.+Habetsauthor=J.+Zhangauthor=J.+Linauthor=T.+Ewingauthor=B.+Matusowauthor=G.+Tsangauthor=A.+Marimuthuauthor=H.+Choauthor=G.+Wuauthor=W.+Wangauthor=D.+Fongauthor=H.+Nguyenauthor=S.+Shiauthor=P.+Womackauthor=M.+Nespiauthor=R.+Shellooeauthor=H.+Cariasauthor=B.+Powellauthor=E.+Lightauthor=L.+Sanftnerauthor=J.+Waltersauthor=J.+Tsaiauthor=B.+L.+Westauthor=G.+Visorauthor=H.+Rezaeiauthor=P.+S.+Linauthor=K.+Nolopauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=G.+Bollag&title=RAF+Inhibitors+that+Evade+Paradoxical+MAPK+Pathway+Activation&doi=10.1038%2Fnature14982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors that evade paradoxical MAPK pathway activation</span></div><div class="casAuthors">Zhang, Chao; Spevak, Wayne; Zhang, Ying; Burton, Elizabeth A.; Ma, Yan; Habets, Gaston; Zhang, Jiazhong; Lin, Jack; Ewing, Todd; Matusow, Bernice; Tsang, Garson; Marimuthu, Adhirai; Cho, Hanna; Wu, Guoxian; Wang, Weiru; Fong, Daniel; Nguyen, Hoa; Shi, Songyuan; Womack, Patrick; Nespi, Marika; Shellooe, Rafe; Carias, Heidi; Powell, Ben; Light, Emily; Sanftner, Laura; Walters, Jason; Tsai, James; West, Brian L.; Visor, Gary; Rezaei, Hamid; Lin, Paul S.; Nolop, Keith; Ibrahim, Prabha N.; Hirth, Peter; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7574</span>),
    <span class="NLM_cas:pages">583-586</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Oncogenic activation of BRAF fuels cancer growth by constitutively promoting RAS-independent mitogen-activated protein kinase (MAPK) pathway signalling.  Accordingly, RAF inhibitors have brought substantially improved personalized treatment of metastatic melanoma.  However, these targeted agents have also revealed an unexpected consequence: stimulated growth of certain cancers.  Structurally diverse ATP-competitive RAF inhibitors can either inhibit or paradoxically activate the MAPK pathway, depending whether activation is by BRAF mutation or by an upstream event, such as RAS mutation or receptor tyrosine kinase activation.  Here we have identified next-generation RAF inhibitors (dubbed 'paradox breakers') that suppress mutant BRAF cells without activating the MAPK pathway in cells bearing upstream activation.  In cells that express the same HRAS mutation prevalent in squamous tumors from patients treated with RAF inhibitors, the first-generation RAF inhibitor vemurafenib stimulated in vitro and in vivo growth and induced expression of MAPK pathway response genes; by contrast the paradox breakers PLX7904 and PLX8394 had no effect.  Paradox breakers also overcame several known mechanisms of resistance to first-generation RAF inhibitors.  Dissocg. MAPK pathway inhibition from paradoxical activation might yield both improved safety and more durable efficacy than first-generation RAF inhibitors, a concept currently undergoing human clin. evaluation with PLX8394.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv_s6rL_GkBbVg90H21EOLACvtfcHk0ljC5mR2-kGScg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWitLfN&md5=e5e4c5e11a6c54d442a4ed7a2f21d76a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature14982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14982%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DEwing%26aufirst%3DT.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWomack%26aufirst%3DP.%26aulast%3DNespi%26aufirst%3DM.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLight%26aufirst%3DE.%26aulast%3DSanftner%26aufirst%3DL.%26aulast%3DWalters%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DVisor%26aufirst%3DG.%26aulast%3DRezaei%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DRAF%2520Inhibitors%2520that%2520Evade%2520Paradoxical%2520MAPK%2520Pathway%2520Activation%26jtitle%3DNature%26date%3D2015%26volume%3D526%26spage%3D583%26epage%3D586%26doi%3D10.1038%2Fnature14982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Effects of RAF Dimerization and its Inhibition on Normal and Disease-Associated RAF Signaling</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2012.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.molcel.2012.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=23352452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=751-758&author=A.+K.+Freemanauthor=D.+A.+Rittauthor=D.+K.+Morrison&title=Effects+of+RAF+Dimerization+and+its+Inhibition+on+Normal+and+Disease-Associated+RAF+Signaling&doi=10.1016%2Fj.molcel.2012.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling</span></div><div class="casAuthors">Freeman, Alyson K.; Ritt, Daniel A.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">751-758</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Raf kinases are essential for normal Ras-Raf-MEK-ERK pathway signaling, and activating mutations in components of this pathway are assocd. with a variety of human cancers, as well as the related developmental disorders Noonan, LEOPARD, and cardiofaciocutaneous syndromes.  Although the Raf kinases are known to dimerize during normal and disease-assocd. Raf signaling, the functional significance of Raf dimerization has not been fully elucidated.  Here, using mutational anal. and a peptide inhibitor, we show that dimerization is required for normal Ras-dependent Raf activation and for the biol. function of disease-assocd. Raf mutants with moderate, low, or impaired kinase activity.  However, dimerization is not needed for the function of B-Raf mutants with high catalytic activity, such as V600E-B-Raf.  Importantly, we find that a dimer interface peptide can effectively block Raf dimerization and inhibit Raf signaling when dimerization is required for Raf function, thus identifying the Raf dimer interface as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_CXtQf2fRqbVg90H21EOLACvtfcHk0ljC5mR2-kGScg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCqtr8%253D&md5=7c8dfaa1a8c01cd4d87cbd8ef364df8d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DA.%2BK.%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DEffects%2520of%2520RAF%2520Dimerization%2520and%2520its%2520Inhibition%2520on%2520Normal%2520and%2520Disease-Associated%2520RAF%2520Signaling%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D49%26spage%3D751%26epage%3D758%26doi%3D10.1016%2Fj.molcel.2012.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critton, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of a BRAF Kinase Domain Monomer Explains Basis for Allosteric Regulation</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnsmb.2924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=25437913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCksr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=37-44&issue=1&author=N.+Thevakumaranauthor=H.+Lavoieauthor=D.+A.+Crittonauthor=A.+Tebbenauthor=A.+Marinierauthor=F.+Sicheriauthor=M.+Therrien&title=Crystal+Structure+of+a+BRAF+Kinase+Domain+Monomer+Explains+Basis+for+Allosteric+Regulation&doi=10.1038%2Fnsmb.2924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation</span></div><div class="casAuthors">Thevakumaran, Neroshan; Lavoie, Hugo; Critton, David A.; Tebben, Andrew; Marinier, Anne; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reported RAF kinase domain structures adopt a side-to-side dimer configuration reflective of an 'on' state that underpins an allosteric mechanism of regulation.  Atomic details of the monomer 'off' state have been elusive.  Reinspection of the BRAF kinase domain structures revealed that sulfonamide inhibitors induce features of an off state, primarily a laterally displaced helix αC stabilized by the activation segment helix 1 (AS-H1).  These features correlated with the ability of sulfonamides to disrupt human BRAF homodimers in cells, in vitro and in crystals yielding a structure of BRAF in a monomer state.  The crystal structure revealed exaggerated, nonproductive positions of helix αC and AS-H1, the latter of which is the target of potent BRAF oncogenic mutations.  Together, this work provides formal proof of an allosteric link between the RAF dimer interface, the activation segment and the catalytic infrastructure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2mmFDDNHIrLVg90H21EOLACvtfcHk0lha_DUvSqXjSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCksr7I&md5=0417ca047f52f6a425a3925fec6b5e05</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2924%26sid%3Dliteratum%253Aachs%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DCritton%26aufirst%3DD.%2BA.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DCrystal%2520Structure%2520of%2520a%2520BRAF%2520Kinase%2520Domain%2520Monomer%2520Explains%2520Basis%2520for%2520Allosteric%2520Regulation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26issue%3D1%26spage%3D37%26epage%3D44%26doi%3D10.1038%2Fnsmb.2924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevakumaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavory, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padeganeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors that Stabilize a Closed RAF Kinase Domain Conformation Induce Dimerization</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1038%2Fnchembio.1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=23685672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=428-436&issue=7&author=H.+Lavoieauthor=N.+Thevakumaranauthor=G.+Gavoryauthor=J.+J.+Liauthor=A.+Padeganehauthor=S.+Guiralauthor=J.+Duchaineauthor=D.+Y.+Maoauthor=M.+Bouvierauthor=F.+Sicheriauthor=M.+Therrien&title=Inhibitors+that+Stabilize+a+Closed+RAF+Kinase+Domain+Conformation+Induce+Dimerization&doi=10.1038%2Fnchembio.1257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span></div><div class="casAuthors">Lavoie, Hugo; Thevakumaran, Neroshan; Gavory, Gwenaelle; Li, John J.; Padeganeh, Abbas; Guiral, Sebastien; Duchaine, Jean; Mao, Daniel Y. L.; Bouvier, Michel; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF kinases have a prominent role in cancer.  Their mode of activation is complex but critically requires dimerization of their kinase domains.  Unexpectedly, several ATP-competitive RAF inhibitors were recently found to promote dimerization and transactivation of RAF kinases in a RAS-dependent manner and, as a result, undesirably stimulate RAS/ERK pathway-mediated cell growth.  The mechanism by which these inhibitors induce RAF kinase domain dimerization remains unclear.  Here we describe bioluminescence resonance energy transfer-based biosensors for the extended RAF family that enable the detection of RAF dimerization in living cells.  Notably, we demonstrate the utility of these tools for profiling kinase inhibitors that selectively modulate RAF dimerization and for probing structural determinants of RAF dimerization in vivo.  Our findings, which seem generalizable to other kinase families allosterically regulated by kinase domain dimerization, suggest a model whereby ATP-competitive inhibitors mediate RAF dimerization by stabilizing a rigid closed conformation of the kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEtTJvsZ1FrVg90H21EOLACvtfcHk0lha_DUvSqXjSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D&md5=f866ae6da93c5e2d7fec53b8dc0e6f2a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1257%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DGavory%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DPadeganeh%26aufirst%3DA.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DD.%2BY.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DInhibitors%2520that%2520Stabilize%2520a%2520Closed%2520RAF%2520Kinase%2520Domain%2520Conformation%2520Induce%2520Dimerization%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D7%26spage%3D428%26epage%3D436%26doi%3D10.1038%2Fnchembio.1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krepler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lujambio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity Against Oncogenic BRAF Signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.ccell.2016.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=27523909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=485-498&author=Z.+Karouliaauthor=Y.+Wuauthor=T.+A.+Ahmedauthor=Q.+Xinauthor=J.+Bollardauthor=C.+Kreplerauthor=X.+Wuauthor=C.+Zhangauthor=G.+Bollagauthor=M.+Herlynauthor=J.+A.+Faginauthor=A.+Lujambioauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=An+Integrated+Model+of+RAF+Inhibitor+Action+Predicts+Inhibitor+Activity+Against+Oncogenic+BRAF+Signaling&doi=10.1016%2Fj.ccell.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling</span></div><div class="casAuthors">Karoulia, Zoi; Wu, Yang; Ahmed, Tamer A.; Xin, Qisheng; Bollard, Julien; Krepler, Clemens; Wu, Xuewei; Zhang, Chao; Bollag, Gideon; Herlyn, Meenhard; Fagin, James A.; Lujambio, Amaia; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-498</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The complex biochem. effects of RAF inhibitors account for both the effectiveness and mechanisms of resistance to these drugs, but a unified mechanistic model has been lacking.  Here we show that RAF inhibitors exert their effects via two distinct allosteric mechanisms.  Drug resistance due to dimerization is detd. by the position of the αC helix stabilized by inhibitor, whereas inhibitor-induced RAF priming and dimerization are the result of inhibitor-induced formation of the RAF/RAS-GTP complex.  The biochem. effect of RAF inhibitor in cells is the combined outcome of the two mechanisms.  Therapeutic strategies including αC-helix-IN inhibitors are more effective in multiple mutant BRAF-driven tumor models, including colorectal and thyroid BRAFV600E cancers, in which first-generation RAF inhibitors have been ineffective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9VLWvQ7ojJrVg90H21EOLACvtfcHk0lha_DUvSqXjSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I&md5=197711577048b889ea1dac8c87049a01</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DBollard%26aufirst%3DJ.%26aulast%3DKrepler%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DLujambio%26aufirst%3DA.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DAn%2520Integrated%2520Model%2520of%2520RAF%2520Inhibitor%2520Action%2520Predicts%2520Inhibitor%2520Activity%2520Against%2520Oncogenic%2520BRAF%2520Signaling%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D485%26epage%3D498%26doi%3D10.1016%2Fj.ccell.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventocilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksimoska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span> <span> </span><span class="NLM_article-title">Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF<sup>V600E</sup> Conformation</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2876</span>– <span class="NLM_lpage">2888</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2876-2888&issue=10&author=M.+Grassoauthor=M.+A.+Estradaauthor=C.+Ventocillaauthor=M.+Samantaauthor=J.+Maksimoskaauthor=J.+Villanuevaauthor=J.+D.+Winklerauthor=R.+Marmorstein&title=Chemically+Linked+Vemurafenib+Inhibitors+Promote+an+Inactive+BRAFV600E+Conformation&doi=10.1021%2Facschembio.6b00529"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00529%26sid%3Dliteratum%253Aachs%26aulast%3DGrasso%26aufirst%3DM.%26aulast%3DEstrada%26aufirst%3DM.%2BA.%26aulast%3DVentocilla%26aufirst%3DC.%26aulast%3DSamanta%26aufirst%3DM.%26aulast%3DMaksimoska%26aufirst%3DJ.%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DMarmorstein%26aufirst%3DR.%26atitle%3DChemically%2520Linked%2520Vemurafenib%2520Inhibitors%2520Promote%2520an%2520Inactive%2520BRAFV600E%2520Conformation%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D10%26spage%3D2876%26epage%3D2888%26doi%3D10.1021%2Facschembio.6b00529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basile, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartsough, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplin, A. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mutant BRAF Splice Variant Signaling By Next-Generation, Selective RAF Inhibitors</span>. <i>Pigm. Cell Melanoma Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1111/pcmr.12218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1111%2Fpcmr.12218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=24422853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2nsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=479-484&author=K.+J.+Basileauthor=K.+Leauthor=E.+J.+Hartsoughauthor=A.+E.+Aplin&title=Inhibition+of+Mutant+BRAF+Splice+Variant+Signaling+By+Next-Generation%2C+Selective+RAF+Inhibitors&doi=10.1111%2Fpcmr.12218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors</span></div><div class="casAuthors">Basile, Kevin J.; Le, Kaitlyn; Hartsough, Edward J.; Aplin, Andrew E.</div><div class="citationInfo"><span class="NLM_cas:title">Pigment Cell & Melanoma Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-484</span>CODEN:
                <span class="NLM_cas:coden">PCMRCM</span>;
        ISSN:<span class="NLM_cas:issn">1755-1471</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Vemurafenib and dabrafenib block MEK-ERK1/2 signaling and cause tumor regression in the majority of advanced-stage BRAFV600E melanoma patients; however, acquired resistance and paradoxical signaling have driven efforts for more potent and selective RAF inhibitors.  Next-generation RAF inhibitors, such as PLX7904 (PB04), effectively inhibit RAF signaling in BRAFV600E melanoma cells without paradoxical effects in wild-type cells.  Furthermore, PLX7904 blocks the growth of vemurafenib-resistant BRAFV600E cells that express mutant NRAS.  Acquired resistance to vemurafenib and dabrafenib is also frequently driven by expression of mutation BRAF splice variants; thus, we tested the effects of PLX7904 and its clin. analog, PLX8394 (PB03), in BRAFV600E splice variant-mediated vemurafenib-resistant cells.  We show that paradox-breaker RAF inhibitors potently block MEK-ERK1/2 signaling, G1/S cell cycle events, survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAFV600E splice variants.  These data support the further investigation of paradox-breaker RAF inhibitors as a second-line treatment option for patients failing on vemurafenib or dabrafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovvoDjV1fbw7Vg90H21EOLACvtfcHk0lh1urTbDcgjHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2nsbs%253D&md5=e9d363cc4fff1821674569c31b8980ee</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fpcmr.12218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcmr.12218%26sid%3Dliteratum%253Aachs%26aulast%3DBasile%26aufirst%3DK.%2BJ.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DHartsough%26aufirst%3DE.%2BJ.%26aulast%3DAplin%26aufirst%3DA.%2BE.%26atitle%3DInhibition%2520of%2520Mutant%2520BRAF%2520Splice%2520Variant%2520Signaling%2520By%2520Next-Generation%252C%2520Selective%2520RAF%2520Inhibitors%26jtitle%3DPigm.%2520Cell%2520Melanoma%2520Res.%26date%3D2014%26volume%3D27%26spage%3D479%26epage%3D484%26doi%3D10.1111%2Fpcmr.12218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tutuka, C. S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariadason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behren, A.</span></span> <span> </span><span class="NLM_article-title">PLX8394, A New Generation BRAF Inhibitor, Selectively Inhibits BRAF in Colonic Adenocarcinoa Cells and Prevents Paradoxical MAPK Pathway Activation</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">112</span>, <span class="refDoi"> DOI: 10.1186/s12943-017-0684-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1186%2Fs12943-017-0684-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=28659148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A280%3ADC%252BC1cjislamsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=112&author=C.+S.+A.+Tutukaauthor=M.+C.+Andrewsauthor=J.+M.+Mariadasonauthor=P.+Ioannidisauthor=C.+Hudsonauthor=J.+Cebonauthor=A.+Behren&title=PLX8394%2C+A+New+Generation+BRAF+Inhibitor%2C+Selectively+Inhibits+BRAF+in+Colonic+Adenocarcinoa+Cells+and+Prevents+Paradoxical+MAPK+Pathway+Activation&doi=10.1186%2Fs12943-017-0684-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation</span></div><div class="casAuthors">Tutuka Candani S A; Andrews Miles C; Mariadason John M; Ioannidis Paul; Hudson Christopher; Cebon Jonathan; Behren Andreas; Andrews Miles C; Cebon Jonathan; Andrews Miles C; Mariadason John M; Cebon Jonathan; Behren Andreas; Cebon Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BRAF inhibitors (BRAFi) are standard of care for the treatment of BRAF V600 mutation-driven metastatic melanoma, but can lead to paradoxical activation of the mitogen-activated protein kinase (MAPK) signalling pathway.  This can result in the promotion of precancerous lesions and secondary neoplasms, mainly (but not exclusively) associated with pre-existing mutations in RAS genes.  We previously reported a patient with synchronous BRAF-mutated metastatic melanoma and BRAF (wt) /KRAS (G12D)-metastatic colorectal cancer (CRC), whose CRC relapsed and progressed when treated with the BRAF inhibitor dabrafenib (GSK2118436).  We used tissue from the resected CRC metastasis to derive a cell line, LM-COL-1, which directly and reliably mimicked the clinical scenario including paradoxical activation of the MAPK signalling pathway resulting in increased cell proliferation upon dabrafenib treatment.  Novel BRAF inhibitors (PLX8394 and PLX7904), dubbed as "paradox breakers", were developed to inhibit V600 mutated oncogenic BRAF without causing paradoxical MAPK pathway activation.  In this study we used our LM-COL-1 model alongside multiple other CRC cell lines with varying mutational backgrounds to demonstrate and confirm that the paradox breaker PLX8394 retains on-target inhibition of mutated BRAF V600 without paradoxically promoting MAPK signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROdjRUxyfsDzDnmmyUf5qOfW6udTcc2eZ60xy5WUHf3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjislamsw%253D%253D&md5=05424c425e63d4e55e491a1e4c52edfb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs12943-017-0684-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-017-0684-x%26sid%3Dliteratum%253Aachs%26aulast%3DTutuka%26aufirst%3DC.%2BS.%2BA.%26aulast%3DAndrews%26aufirst%3DM.%2BC.%26aulast%3DMariadason%26aufirst%3DJ.%2BM.%26aulast%3DIoannidis%26aufirst%3DP.%26aulast%3DHudson%26aufirst%3DC.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DBehren%26aufirst%3DA.%26atitle%3DPLX8394%252C%2520A%2520New%2520Generation%2520BRAF%2520Inhibitor%252C%2520Selectively%2520Inhibits%2520BRAF%2520in%2520Colonic%2520Adenocarcinoa%2520Cells%2520and%2520Prevents%2520Paradoxical%2520MAPK%2520Pathway%2520Activation%26jtitle%3DMol.%2520Cancer%26date%3D2017%26volume%3D16%26spage%3D112%26doi%3D10.1186%2Fs12943-017-0684-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okaniwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsutsumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tottori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">6478</span>– <span class="NLM_lpage">6494</span>, <span class="refDoi"> DOI: 10.1021/jm400778d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400778d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6478-6494&author=M.+Okaniwaauthor=M.+Hiroseauthor=T.+Aritaauthor=M.+Yabukiauthor=A.+Nakamuraauthor=T.+Takagiauthor=T.+Kawamotoauthor=N.+Uchiyamaauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=T.+Tottoriauthor=Y.+Inuiauthor=B.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Discovery+of+a+Selective+Kinase+Inhibitor+%28TAK-632%29+Targeting+Pan-RAF+Inhibition%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+C-7-Substituted+1%2C3-Benzothiazole+Derivatives&doi=10.1021%2Fjm400778d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives</span></div><div class="casAuthors">Okaniwa, Masanori; Hirose, Masaaki; Arita, Takeo; Yabuki, Masato; Nakamura, Akito; Takagi, Terufumi; Kawamoto, Tomohiro; Uchiyama, Noriko; Sumita, Akihiko; Tsutsumi, Shunichirou; Tottori, Tsuneaki; Inui, Yoshitaka; Sang, Bi-Ching; Yano, Jason; Aertgeerts, Kathleen; Yoshida, Sei; Ishikawa, Tomoyasu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6478-6494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivs. based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 inhibitor and developed a regioselective cyclization methodol. for the C-7-substituted 1,3-benzothiazole scaffold utilizing meta-substituted anilines.  Eventually, we selected 7-cyano deriv. I (TAK-632) as a development candidate and confirmed its binding mode by cocrystal structure with BRAF.  Accommodation of the 7-cyano group into the BRAF-selectivity pocket and the 3-(trifluoromethyl)phenyl acetamide moiety into the hydrophobic back pocket of BRAF in the DFG-out conformation contributed to enhanced RAF potency and selectivity vs VEGFR2.  Reflecting its potent pan-RAF inhibition and slow off-rate profile, I demonstrated significant cellular activity against mutated BRAF or mutated NRAS cancer cell lines.  Furthermore, in both A375 (BRAFV600E) and HMVII (NRASQ61K) xenograft models in rats, I demonstrated regressive antitumor efficacy by twice daily, 14-day repetitive administration without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2jcxKx47lWLVg90H21EOLACvtfcHk0lh1urTbDcgjHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qsrzL&md5=60ccb75bcf7d7772cdf21468e26c141f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm400778d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400778d%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DTottori%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DY.%26aulast%3DSang%26aufirst%3DB.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520Kinase%2520Inhibitor%2520%2528TAK-632%2529%2520Targeting%2520Pan-RAF%2520Inhibition%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520C-7-Substituted%25201%252C3-Benzothiazole%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6478%26epage%3D6494%26doi%3D10.1021%2Fjm400778d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donelan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouitar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carideo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okaniwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7043</span>– <span class="NLM_lpage">7055</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1158%2F0008-5472.CAN-13-1825" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=7043-7055&issue=23&author=A.+Nakamuraauthor=T.+Aritaauthor=S.+Tsuchiyaauthor=J.+Donelanauthor=J.+Chouitarauthor=E.+Carideoauthor=K.+Galvinauthor=M.+Okaniwaauthor=T.+Ishikawaauthor=S.+Yoshida&title=Antitumor+Activity+of+the+Selective+Pan-RAF+Inhibitor+TAK-632+in+BRAF+Inhibitor-Resistant+Melanoma&doi=10.1158%2F0008-5472.CAN-13-1825"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1825%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DDonelan%26aufirst%3DJ.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DCarideo%26aufirst%3DE.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DS.%26atitle%3DAntitumor%2520Activity%2520of%2520the%2520Selective%2520Pan-RAF%2520Inhibitor%2520TAK-632%2520in%2520BRAF%2520Inhibitor-Resistant%2520Melanoma%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D23%26spage%3D7043%26epage%3D7055%26doi%3D10.1158%2F0008-5472.CAN-13-1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risom, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturgis, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegtli, W. C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine Inhibitors of B-RAF(V600E). Part 4: Rational Design and Kinase Selectivity Profile of Cell Potent Type II Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6237</span>– <span class="NLM_lpage">6241</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.bmcl.2012.08.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6237-6241&author=S.+Wenglowskyauthor=D.+Morenoauthor=E.+R.+Lairdauthor=S.+L.+Gloorauthor=L.+Renauthor=T.+Risomauthor=J.+Rudolphauthor=H.+L.+Sturgisauthor=W.+C.+Voegtli&title=Pyrazolopyridine+Inhibitors+of+B-RAF%28V600E%29.+Part+4%3A+Rational+Design+and+Kinase+Selectivity+Profile+of+Cell+Potent+Type+II+Inhibitors&doi=10.1016%2Fj.bmcl.2012.08.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26atitle%3DPyrazolopyridine%2520Inhibitors%2520of%2520B-RAF%2528V600E%2529.%2520Part%25204%253A%2520Rational%2520Design%2520and%2520Kinase%2520Selectivity%2520Profile%2520of%2520Cell%2520Potent%2520Type%2520II%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6237%26epage%3D6241%26doi%3D10.1016%2Fj.bmcl.2012.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jambrina, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilkington, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybakova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodenko, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchete, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosta, E.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1002/anie.201509272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1002%2Fanie.201509272" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=983-986&author=P.+G.+Jambrinaauthor=N.+Rauchauthor=R.+Pilkingtonauthor=K.+Rybakovaauthor=L.+K.+Nguyenauthor=B.+N.+Kholodenkoauthor=N.+Bucheteauthor=W.+Kolchauthor=E.+Rosta&title=Phosphorylation+of+RAF+Kinase+Dimers+Drives+Conformational+Changes+that+Facilitate+Transactivation&doi=10.1002%2Fanie.201509272"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201509272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201509272%26sid%3Dliteratum%253Aachs%26aulast%3DJambrina%26aufirst%3DP.%2BG.%26aulast%3DRauch%26aufirst%3DN.%26aulast%3DPilkington%26aufirst%3DR.%26aulast%3DRybakova%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DL.%2BK.%26aulast%3DKholodenko%26aufirst%3DB.%2BN.%26aulast%3DBuchete%26aufirst%3DN.%26aulast%3DKolch%26aufirst%3DW.%26aulast%3DRosta%26aufirst%3DE.%26atitle%3DPhosphorylation%2520of%2520RAF%2520Kinase%2520Dimers%2520Drives%2520Conformational%2520Changes%2520that%2520Facilitate%2520Transactivation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D983%26epage%3D986%26doi%3D10.1002%2Fanie.201509272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&issue=6&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+Activation+of+the+RAF-ERK+Signaling+Pathway+by+Oncogenic+Mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0ljwhG9YXErJ3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520Activation%2520of%2520the%2520RAF-ERK%2520Signaling%2520Pathway%2520by%2520Oncogenic%2520Mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26issue%3D6%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlattl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalkuhl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1158%2F1535-7163.MCT-15-0617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=26916115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=354-365&issue=3&author=I.+C.+Waizeneggerauthor=A.+Baumauthor=S.+Steurerauthor=H.+Stadtmullerauthor=G.+Baderauthor=O.+Schaafauthor=P.+Garin-Chesaauthor=A.+Schlattlauthor=N.+Schweiferauthor=C.+Haslingerauthor=F.+Colbatzkyauthor=S.+Mousaauthor=A.+Kalkuhlauthor=N.+Krautauthor=G.+R.+Adolf&title=A+Novel+RAF+Kinase+Inhibitor+with+DFG-Out-Binding+Mode%3A+High+Efficacy+in+BRAF-Mutant+Tumor+Xenograft+Models+in+the+Absence+of+Normal+Tissue+Hyperproliferation&doi=10.1158%2F1535-7163.MCT-15-0617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span></div><div class="casAuthors">Waizenegger, Irene C.; Baum, Anke; Steurer, Steffen; Stadtmuller, Heinz; Bader, Gerd; Schaaf, Otmar; Garin-Chesa, Pilar; Schlattl, Andreas; Schweifer, Norbert; Haslinger, Christian; Colbatzky, Florian; Mousa, Sien; Kalkuhl, Arno; Kraut, Norbert; Adolf, Gunther R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">354-365</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BI 882370 is a highly potent and selective RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase.  The compd. inhibited proliferation of human BRAF-mutant melanoma cells with 100× higher potency (1-10 nmol/L) than vemurafenib, whereas wild-type cells were not affected at 1,000 nmol/L.  BI 882370 administered orally was efficacious in multiple mouse models of BRAF-mutant melanomas and colorectal carcinomas, and at 25 mg/kg twice daily showed superior efficacy compared with vemurafenib, dabrafenib, or trametinib (dosed to provide exposures reached in patients).  To model drug resistance, A375 melanoma-bearing mice were initially treated with vemurafenib; all tumors responded with regression, but the majority subsequently resumed growth.  Trametinib did not show any efficacy in this progressing population.  BI 882370 induced tumor regression; however, resistance developed within 3 wk.  BI 882370 in combination with trametinib resulted in more pronounced regressions, and resistance was not obsd. during 5 wk of second-line therapy.  Importantly, mice treated with BI 882370 did not show any body wt. loss or clin. signs of intolerability, and no pathol. changes were obsd. in several major organs investigated, including skin.  Furthermore, a pilot study in rats (up to 60 mg/kg daily for 2 wk) indicated lack of toxicity in terms of clin. chem., hematol., pathol., and toxicogenomics.  Our results indicate the feasibility of developing novel compds. that provide an improved therapeutic window compared with first-generation BRAF inhibitors, resulting in more pronounced and long-lasting pathway suppression and thus improved efficacy.  Mol Cancer Ther; 15(3); 354-65. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmtRl_zbyDibVg90H21EOLACvtfcHk0ljmXXZsiE6a2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D&md5=e35140e31364622de51538b99618001a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0617%26sid%3Dliteratum%253Aachs%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DStadtmuller%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSchaaf%26aufirst%3DO.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DSchlattl%26aufirst%3DA.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DMousa%26aufirst%3DS.%26aulast%3DKalkuhl%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DA%2520Novel%2520RAF%2520Kinase%2520Inhibitor%2520with%2520DFG-Out-Binding%2520Mode%253A%2520High%2520Efficacy%2520in%2520BRAF-Mutant%2520Tumor%2520Xenograft%2520Models%2520in%2520the%2520Absence%2520of%2520Normal%2520Tissue%2520Hyperproliferation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D3%26spage%3D354%26epage%3D365%26doi%3D10.1158%2F1535-7163.MCT-15-0617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bregman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaida, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babij, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnahan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span> <span> </span><span class="NLM_article-title">Purinylpyridinylamino-Based DFG-In/αC-Helix-Out B-RAF Inhibitors: Applying Mutant Versus Wild-Type B-RAF Selectivity Indices for Compound Profiling</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2215</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=10.1016%2Fj.bmc.2016.03.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=27085672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVarsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2215-2234&author=L.+Liuauthor=M.+R.+Leeauthor=J.+L.+Kimauthor=D.+A.+Whittingtonauthor=H.+Bregmanauthor=Z.+Huaauthor=R.+T.+Lewisauthor=M.+W.+Martinauthor=N.+Nishimuraauthor=M.+Potashmanauthor=K.+Yangauthor=S.+Yiauthor=K.+R.+Vaidaauthor=L.+F.+Epsteinauthor=C.+Babijauthor=M.+Fernandoauthor=J.+Carnahanauthor=M.+H.+Norman&title=Purinylpyridinylamino-Based+DFG-In%2F%CE%B1C-Helix-Out+B-RAF+Inhibitors%3A+Applying+Mutant+Versus+Wild-Type+B-RAF+Selectivity+Indices+for+Compound+Profiling&doi=10.1016%2Fj.bmc.2016.03.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling</span></div><div class="casAuthors">Liu, Longbin; Lee, Matthew R.; Kim, Joseph L.; Whittington, Douglas A.; Bregman, Howard; Hua, Zihao; Lewis, Richard T.; Martin, Matthew W.; Nishimura, Nobuko; Potashman, Michele; Yang, Kevin; Yi, Shuyan; Vaida, Karina R.; Epstein, Linda F.; Babij, Carol; Fernando, Manory; Carnahan, Josette; Norman, Mark H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2215-2234</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">One of the challenges for targeting B-RafV600E with small mol. inhibitors had been achieving adequate selectivity over the wild-type protein B-RafWT, as inhibition of the latter has been assocd. with hyperplasia in normal tissues.  Recent studies suggest that B-Raf inhibitors inducing the 'DFG-in/αC-helix-out' conformation (Type IIB) likely will exhibit improved selectivity for B-RafV600E.  To explore this hypothesis, we transformed Type IIA inhibitor (1) into a series of Type IIB inhibitors (sulfonamides and sulfamides 4-6) and examd. the SAR.  Three selectivity indexes were introduced to facilitate the analyses: the B-RafV600E/B-RafWT biochem. (bS), cellular (cS) selectivity, and the phospho-ERK activation (pA).  Our data indicates that α-branched sulfonamides and sulfamides show higher selectivities than the linear derivs.  We rationalized this finding based on anal. of structural information from the literature and provided evidence for a monomeric B-Raf-inhibitor complex previously hypothesized to be responsible for the desired B-RafV600E selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2yyHmmmdGKrVg90H21EOLACvtfcHk0ljmXXZsiE6a2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVarsbc%253D&md5=5829f989b56e20539a03b78f376017c4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.055%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DBregman%26aufirst%3DH.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYi%26aufirst%3DS.%26aulast%3DVaida%26aufirst%3DK.%2BR.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26atitle%3DPurinylpyridinylamino-Based%2520DFG-In%252F%25CE%25B1C-Helix-Out%2520B-RAF%2520Inhibitors%253A%2520Applying%2520Mutant%2520Versus%2520Wild-Type%2520B-RAF%2520Selectivity%2520Indices%2520for%2520Compound%2520Profiling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D2215%26epage%3D2234%26doi%3D10.1016%2Fj.bmc.2016.03.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz-Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span> <span> </span><span class="NLM_article-title">Ligand Recognition by E- and P-Selectin: Chemoenzymatic Synthesis and Inhibitory Activity of Bivalent Sialyl Lewis x Derivatives and Sialyl Lewis x Carboxylic Acid</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5137</span>– <span class="NLM_lpage">5143</span>, <span class="refDoi"> DOI: 10.1021/jo980350s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo980350s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1998&pages=5137-5143&author=V.+Wittmannauthor=S.+Takayamaauthor=K.+W.+Gongauthor=G.+Weitz-Schmidtauthor=C.+Wong&title=Ligand+Recognition+by+E-+and+P-Selectin%3A+Chemoenzymatic+Synthesis+and+Inhibitory+Activity+of+Bivalent+Sialyl+Lewis+x+Derivatives+and+Sialyl+Lewis+x+Carboxylic+Acid&doi=10.1021%2Fjo980350s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjo980350s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo980350s%26sid%3Dliteratum%253Aachs%26aulast%3DWittmann%26aufirst%3DV.%26aulast%3DTakayama%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DK.%2BW.%26aulast%3DWeitz-Schmidt%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DC.%26atitle%3DLigand%2520Recognition%2520by%2520E-%2520and%2520P-Selectin%253A%2520Chemoenzymatic%2520Synthesis%2520and%2520Inhibitory%2520Activity%2520of%2520Bivalent%2520Sialyl%2520Lewis%2520x%2520Derivatives%2520and%2520Sialyl%2520Lewis%2520x%2520Carboxylic%2520Acid%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1998%26volume%3D63%26spage%3D5137%26epage%3D5143%26doi%3D10.1021%2Fjo980350s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KSP','PDB','4KSP'); return false;">PDB: 4KSP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2','PDB','5JT2'); return false;">PDB: 5JT2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G9R','PDB','4G9R'); return false;">PDB: 4G9R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RZW','PDB','4RZW'); return false;">PDB: 4RZW</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i33"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00499">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_31558"></div></div></div></div></div><hr /></hr><p class="last">This material is available free of charge via The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00499">10.1021/acs.jmedchem.8b00499</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Information related to the sedimentation equilibrium raw data and residuals, as well as R509A mutation sedimentation velocity experiments and Vem-BisAmide-2 sedimentation velocity experiments (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00499/suppl_file/jm8b00499_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00499/suppl_file/jm8b00499_si_001.pdf">jm8b00499_si_001.pdf (515.99 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00499&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-11%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00499%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00499" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a4d8808b33d3c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
